Document:

EX-10.1

 Exhibit 10.1 
  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

THIRD AMENDED AND RESTATED LICENSE 

AND DEVELOPMENT AGREEMENT 

This THIRD AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENT (the “Third Restated Agreement”) is made effective as of
August 26, 2013 (the “Effective Date”) by and among Guided Therapy Systems, LLC, an Arizona limited liability company (“GTS” or “Licensor”), Ardent Sound Inc., an Arizona corporation (“Ardent
Sound” and, together with GTS, “Licensors”), and Ulthera, Inc., a Delaware corporation (“Ulthera” or “Licensee”). GTS or GTS and Ardent Sound, collectively, are hereinafter referred to as a
“Party,” Ulthera is hereinafter referred to as a “Party,” and each of GTS, Ardent Sound and Ulthera are hereinafter collectively referred to as the “Parties.” 

RECITALS 

WHEREAS, the Parties previously entered into that certain License and Development Agreement, dated as of
November 15, 2005 (the “License Agreement”); 
 WHEREAS, the Parties thereafter amended
and restated the License Agreement in the Amended And Restated License And Development Agreement, dated November 21, 2007 (the “First Restated Agreement”); 

WHEREAS, the Parties initially modified the First Restated Agreement in the First Modification To The
Amended And Restated License And Development Agreement, dated April 1, 2010 (the “First Modification”), 

WHEREAS, the Parties subsequently modified the First Restated Agreement in the Second Modification To The Amended And
Restated License And Development Agreement, dated December 9, 2010 (the “Second Modification”); 

WHEREAS, the Parties by way of a letter agreement dated December 5, 2011 entered into certain
non-binding obligations regarding an option to expand the current fields of use to include targeted [***] treatment, and into certain binding obligations for prosecution and payment of patent expenses and fees for certain GTS Patent Rights, past and
in the future (the “Letter Agreement”); 
 WHEREAS, the Parties further amended and restated
the First Restated Agreement in the Second Amended and Restated License and Development Agreement, dated November 1, 2011 (the “Second Restated Agreement”); and 

WHEREAS, the Parties now wish to further amend and restate the Second Restated Agreement to grant Ulthera
a license to certain technology and patents developed by Licensors using ultrasound therapy, or combined ultrasound imaging and therapy, to a human body for the expanded Field of use to include the treatment of [***] on the terms and subject to the
conditions set forth herein. 
 Confidential 

 NOW, THEREFORE, in consideration of the
mutual promises set forth herein, the Parties agree as follows: 
 ARTICLE 1 

Definitions 
 1.1
“Additional Components” means one or more separate products, instruments, components thereof or methods which are sold with a Licensed Product and which are not essential to the function, use or operation of a Licensed Product. 

1.2 “Affiliate” means, in relation to any Party hereto, (a) any entity in which the relevant Party directly or indirectly
holds more than fifty percent (50%) of the voting stock or power, (b) any entity (“Holding Entity”) which holds directly or indirectly more than fifty percent (50%) of the voting stock or power of the relevant Party,
(c) any other entity in which more than fifty percent (50%) of the voting stock or power is directly or indirectly held by any Holding Entity of the relevant Party or (d) any entity in which the relevant Party directly or indirectly
holds less than fifty percent (50%) of the voting stock or power but has management control of such entity in that it has the ability to appoint and remove the majority of the Board of Directors (or other governing body) of such Party. 

1.3 “Ardent-GTS Agreement” means that certain License and Development Agreement between Ardent Sound and GTS, effective as of
November 2005, as amended, granting GTS, among other rights, an exclusive, transferable, sublicenseable license to Ardent Sound Licensed Patent Rights, Ardent Sound Non-Exclusive Patent Rights, and Ardent Sound Know-How to develop, have developed,
use, make, have made, offer for sale, sell, have sold, import or have imported the Licensed Product(s) within the Field in the Territory. 

1.4 “Ardent Sound-Licensed Patent Rights” means the patents and patent applications set forth in Exhibit B, and all other
patents and patent applications owned or otherwise controlled by or licensed by a Third Party to Ardent Sound [***], and any patents and patent applications claiming priority thereto, that claim or cover ultrasound technology and that are necessary
for or otherwise used in the development or commercialization of any Licensed Product. 
 1.5 “Ardent Sound Non-Exclusive Patent
Rights” means the patent and patent applications set forth in Exhibit C that have been licensed on a non-exclusive basis to Ardent Sound, with rights to sublicense, from Ethicon Endo-Surgery under that certain non-exclusive license and
termination agreement between Ardent Sound and Ethicon Endo-Surgery, Inc., dated March 2, 2004, and any patents and patent applications claiming priority thereto. 

1.6 “Bankruptcy Event” means the entity in question becomes insolvent, or voluntary or involuntary proceedings by or against
such entity are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for such 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
entity, or proceedings are instituted by or against such entity for corporate reorganization or the dissolution of such entity, which proceedings, if voluntary, shall not have been dismissed
within sixty (60) days after the date of filing, or such person or entity makes an assignment for the benefit of its creditors, or substantially all of the assets of such entity are seized or attached and not released within sixty
(60) days thereafter. 
 1.7 “Change in Control” means in respect of a Party hereto (i) the liquidation or
dissolution of such Party or the sale or other transfer by such Party (excluding transfers to subsidiaries) of all or substantially all of its assets; or (ii) the occurrence of a tender offer, stock purchase, other stock acquisition, merger,
consolidation, recapitalization, reverse split, sale or transfer of assets or other transaction, as a result of which any person, entity or group (a) becomes the beneficial owner, directly or indirectly, of securities of such Party representing
more than fifty percent (50%) of the ordinary shares of such Party or representing more than fifty percent (50%) of the combined voting power with respect to the election of directors (or members of any other governing body) of such
Party’s then outstanding securities, or (b) obtains the ability to appoint a majority of the Board of Directors (or other governing body) of such Party, or obtains the ability to direct the operations or management of such Party or any
successor to such Party’s business; provided, however, that Change in Control shall not include the issuance by a Party of equity to the public through a public offering or offerings, or the financing of a Party through venture-capital or other
like financing. 
 1.8 “Commercial Exploitation” will have the meaning set forth in Section 4.4. 

1.9 “Development Budget” has the meaning set forth in Section 3.1(a). 

1.10 “Development Period” has the meaning set forth in Section 3.1(a). 

1.11 “Development Services” means the development services to be provided by GTS and/or Ardent Sound to Ulthera according to
an agreed Proposal as set forth in Section 3.1(a) and (b), or pursuant to a development services agreement as set forth in Section 2.5. 

1.12 “Diagnostic Imaging Applications” means any diagnostic-imaging modalities, devices or applications that do not include an
application, product, method or component specifically designed to provide a cosmetic or dermatological treatment effect within the Field. 

1.13 “Execution Date” means the date that this Agreement is signed by both of the Parties. 

1.14 “Face and Neck Applications” means all technologies, products, processes, procedures and other applications, including
without limitation those 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
provided at med spas, within the field of dermatological cosmetic treatment performed by Professionals for providing ultrasound therapy or combined ultrasound imaging and therapy to a face, head,
and/or neck of a human body, including, for example, applications directed to neck, hair, facial, skin (including acne for the face and neck and body), dental improvements, and other similar aesthetic applications. These applications specifically
include, but are not limited to, [***]. For clarity, combined imaging and therapy includes imaging and therapy that may be on a single transducer or array or on two or more transducers or arrays. Notwithstanding the foregoing, Face and Neck
Applications do not include therapies, treatments or clinical applications that are primarily or otherwise intentionally directed to addressing [***]. 

1.15 “Field” means the (i) Face and Neck Applications; (ii) Other Cosmetics Applications; (iii) Targeted
Treatment of [***]; and (iv) Treatment of [***], provided that the rights to the Treatment of [***] shall be forfeited if Ulthera does not satisfy all the [***] criteria under Section 2.5. 

1.16 “First Commercial Sale” means the first good-faith commercial sale of a Licensed Product made to a Third Party and not
for testing or demonstration purposes. 
 1.17 “Funds” has the meaning set forth in Section 2.5. 

1.18 “Further GTS Developments” means all Patent Rights of Licensors [***] that are not currently licensed or not
currently subject to a covenant-not-to-sue to Ulthera, and any patents and patent applications claiming priority thereto. [***] Patent Rights of Licensors known to the Parties to qualify as Further GTS Developments. 

1.19 “GTS Know-How” means all Know-How, including any software used in the Field, developed, owned, or in-licensed by GTS or
its Affiliate, Ardent Sound [***], and related to the Field that (a) is not covered by the GTS Patent Rights but is necessary or useful to manufacture or commercialize the Licensed Products in the Field and (b) is not provided or developed
by Ardent Sound or GTS under the Development Services as Work Product. 
 1.20 “GTS-Exclusively Licensed Patent Rights”
means all Patent Rights under any patents or patent applications claiming priority to, and including, the patents and patent applications set forth in Exhibit A, which include patents and patent applications owned or otherwise controlled by GTS
(including those to which GTS has rights in the Field) [***] that claim or cover ultrasound technology and that are necessary or otherwise used in the development or commercialization of any Licensed Product. Although Exhibit A does not identify all
abandoned applications or patents, for the avoidance of doubt, GTS-Exclusively Licensed Patent Rights include abandoned applications or patents having priority claims and within the family of patents and patent applications listed in Exhibit A. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.21 “GTS Patent Rights” means the GTS-Exclusively Licensed Patent Rights, the
Ardent Sound-Licensed Patent Rights, and Ardent Sound Non-Exclusive Patent Rights. For clarity, GTS Patent Rights does not include Other GTS Developments. 

1.22 “GTS Technology” means collectively GTS Patent Rights and the Patent Rights therein and GTS Know-How. 

1.23 “Imaging Therapeutic Applications” means any imaging and therapeutic or any therapeutic only modalities, devices or
applications that do not include an application, product, method or component specifically designed to provide a cosmetic or dermatological treatment effect within the Field. 

1.24 “Intellectual Property” or “Intellectual Property Rights” means patents, Patent Rights, trademarks, service
marks, trade names, trade dress, copyrights, works of authorship and trade secrets, and any and all registrations and applications for all the foregoing. 

1.25 “Know-How” means all know-how, trade secrets, inventions, data, software and other works of authorship, processes,
techniques, procedures, compositions, devices, methods, formulas, protocols and information, and improvements, whether or not patentable or copyrightable, including, without limitation, all electrical, mechanical, chemical, biochemical,
toxicological and scientific research information. 
 1.26 “Licensed Product” means any product, component thereof or method
of use or manufacturing process within the Field that would, but for the licenses granted under this Agreement, infringe at least one Valid Claim of the GTS Patent Rights in the country in which any such product, component, method or combination
thereof is manufactured, used, imported, offered for sale or sold. 
 1.27 “Net Sales” means the revenue which Ulthera or
its Affiliates actually collect from the sale, transfer, or other disposition for value of the Licensed Product to an unaffiliated Third Party, or to any Affiliate that is an end user of the Licensed Product, less the following amounts:
(a) discounts, including cash discounts, or rebates actually allowed or granted, (b) credits or allowances actually granted upon claims or returns regardless of the reason for the Third Party’s request to return, (c) freight
charges paid for delivery, (d) taxes or other governmental charges levied on or measured by the invoiced amount whether absorbed by the billing or the billed party, and (e) the average sales price of any Additional Components that may be
provided by Ulthera to the buyer of the Licensed Product. 
 1.28 “New GTS Developments” means all Patent Rights under the
patents and patent applications set forth in Exhibit E, Table E-1 and any other patents and patent applications of Licensors [***], and any patents and patent applications claiming priority thereto. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.29 “Other Cosmetic Applications” means all technologies, products, processes,
procedures and other applications, including without limitation those provided at med spas, within the field of dermatological cosmetic treatment performed by Professionals for providing ultrasound therapy, or combined ultrasound imaging and therapy
to a human body below the neck including, for example, applications directed to hair, skin, and other similar aesthetic applications. These applications specifically include, but are not limited to, [***]. For clarity, combined imaging and therapy
includes imaging and therapy that may be on a single transducer or array or on two or more transducers or arrays. Notwithstanding the foregoing, Other Cosmetic Applications do not include therapies, treatments or clinical applications that are
primarily or otherwise intentionally directed to addressing [***]. 
 1.30 “Other GTS Developments” means all Patent Rights
reflected in a patent issued or patent application [***] that is under the New GTS Developments or Outside Field GTS Patent Rights, and any patents and patent applications claiming priority thereto. 

1.31 “Outside Activities” has the meaning set forth in Section 3.4. 

1.32 “Outside Field GTS Patent Rights” has the meaning set forth in Section 2.1(c) including the Patent Rights under the
patents and patent applications set forth in Exhibit E, Table E-2. 
 1.33 “Patent Rights” mean all rights under patents and
patent applications, disclosures of invention and any and all patents issuing therefrom (including utility, model and design patents and certificates of invention), together with any and all substitutions, extensions (including supplemental
protection certificates), registrations, confirmations, reissues, divisionals, continuations, continuations-in-part, re-examinations, renewals and foreign counterparts of the foregoing. 

1.34 “Professionals” means physician-licensed or physician-directed treatment personnel. 

1.35 “Proposal” has the meaning set forth in Section 3.1(a). 

1.36 “Regulatory Agency” means the regulatory agency in a country that performs the equivalent function as the FDA in the
United States, and any reference to a rule or requirement of the FDA herein shall if the circumstances make it applicable refer to the equivalent rule or requirement of any Regulatory Agency. 

1.37 “Specifications” has the meaning set forth in Section 3.1(a). 

1.38 “Targeted Treatment of [***]” means all technologies, products, processes, procedures and other applications,
including without limitation those provided at med spas, within the field of dermatological cosmetic treatment performed by Professionals for providing ultrasound therapy or combined ultrasound imaging and

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
therapy to any part of a human body for the targeted treatment of [***], including [***], or otherwise specifically or selectively targeting [***]. These applications, include, but are not
limited to [***]. Combined imaging and therapy includes imaging and/or therapy that may be on a single transducer or array or two or more transducers or arrays. 

1.39 “Term” shall have the meaning set forth in Article 8. 

1.40 “Territory” means all countries of the world. 

1.41 “Third Party” means any entity other than: GTS, Ardent Sound, Ulthera, or an Affiliate of GTS, Ardent Sound, or Ulthera.

 1.42 “Third Party Acquirer” shall have the meaning set forth in Section 2.1(e)(ii). 

1.43 “Treatment of [***]” means all technologies, products, processes, procedures and other applications, including
without limitation those provided at med spas, within the field of dermatological cosmetic treatment performed by Professionals for providing ultrasound therapy or combined ultrasound imaging and therapy to any part of a human body for the treatment
of [***]. These applications include treatment of [***]. Combined imaging and therapy includes imaging and/or therapy that may be on a single transducer or array or two or more transducers or arrays. 

1.44 “Ulthera-MEEI Agreement” means that certain Settlement Agreement and Release between Ulthera and MEEI, having an
effective date of November 25, 2008, in which MEEI granted certain license rights to certain “MEEI Patent Rights” to Ulthera and its affiliates, licensees, and sublicensees, including GTS. 

1.45 “Ulthera Patent Rights” means all Patent Rights arising in the course of the performance of Development Services under
this Agreement that are (a) conceived of and reduced to practice jointly by employees, agents or contractors of Ulthera and employees, agents or contractors of GTS or Ardent Sound or (b) conceived of and reduced to practice solely by
employees, agents or contractors of GTS or Ardent Sound. Ulthera Patent Rights shall include without limitation the patents and patent applications identified in Exhibit D. 

1.46 “Valid Claim” means a claim of an issued patent included within the GTS Patent Rights, and which claim has not lapsed,
been canceled or become abandoned and has not been declared invalid or unenforceable by an unreversed and unappealable decision or judgment of a court or other appropriate body of competent jurisdiction, and which has not been admitted to be invalid
or unenforceable through reissue, disclaimer or otherwise. 
 1.47 “Work Product” means deliverables including design
specifications, prototypes, software code (executable, object code, and user interface source code, but specifically excluding pre-existing ROOMS source code) schematics, performance 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
characteristics, electronic hardware and test protocols, backup documentation, prototype drawings, models, test procedures, prototype documentation and Know How developed by GTS or Ardent Sound
in accordance with the performance of Development Services, and all Intellectual Property Rights in any of the foregoing. 
 ARTICLE 2 

Grant of License 
 2.1
License for GTS Technology. 
 (a) GTS Patent Rights. Licensors hereby grant to Ulthera an exclusive, sublicenseable license under
their respective rights and interests in the GTS Patent Rights to develop, have developed, use, make, have made, offer for sale, sell, have sold, import or otherwise commercially exploit Licensed Product(s) within the Field in the Territory, and
their exclusive and complete rights under their respective non-exclusive rights and interests in the Ardent Sound Non-Exclusive Rights to develop, have developed, use, make, have made, offer for sale, sell, have sold, import or otherwise
commercially exploit Licensed Product(s) within the Field in the Territory. For clarity, the exclusive rights granted herein are exclusive to Ulthera even as to Licensors. Such exclusive rights notwithstanding, for the avoidance of doubt Licensors
shall be permitted to conduct or otherwise use GTS Technology for activities, including development services for therapy or treatment applications, subject to the restrictions in Section 3.2(c) and Section 3.4. 

(b) GTS Know-How. Licensors hereby grant to Ulthera an exclusive, sublicenseable license under their respective rights and interests in
the GTS Know-How to develop, have developed, use, make, have made, offer for sale, sell, have sold, import or otherwise commercially exploit the Licensed Product(s) within the Field in the Territory. For clarity, the exclusive rights granted herein
are exclusive to Ulthera even as to Licensors. Such exclusive rights notwithstanding, for the avoidance of doubt Licensors shall be permitted to conduct or otherwise use GTS Technology for activities, including development services for therapy or
treatment applications subject to the restrictions in Section 3.2(c) and Section 3.4. 
 (c) Outside Field GTS Patent
Rights. The patents and applications identified on Exhibit E, Table E-2 and labeled “Outside Field GTS Patent Rights,” shall fall outside of Ulthera’s Field to the extent that each and every claim in the patent or application does
not cover any activity within the Field. The parties acknowledge that if the claims change (e.g., through amendment, reissue or re-exam), these patents and applications may fall within the Field and are therefore exclusively licensed to Ulthera in
the Field. For clarity, any Patent Rights claiming priority to or from the patents and applications identified as “Outside Field GTS Patent Rights” on Exhibit E, Table E-2 are exclusively licensed to Ulthera in the Field, if any of the
claims cover any activity within the Field, and are further subject to the provisions applicable to the GTS-Exclusively Licensed Patent Rights, including without limitation the royalty provisions of Section 5.1. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (d) Incidental Effects.  

(i) The Parties appreciate that use in a particular field of use may by its nature also provide incidental effects in another field of use.

 (ii) Each Party hereby agrees that it (or, for clarity, any of its Affiliates or licensees) will not have a cause of action against the
other Party if the other Party is practicing in its field of use even if associated incidental effects occur outside such field of use. For clarity, incidental effects shall include any effects that are unavoidably and necessarily required to
practice in a field licensed or held by the other Party. 
 (iii) Notwithstanding Section 2.1(d)(ii), a cause of action shall be
permitted by a party if the other party markets, advertises or otherwise actively promotes incidental effects that are outside its respective field of use. Moreover, to the extent such marketing, advertisement or promotional activities occurs
through a Party’s licensees and end users, such Party agrees to notify in writing such licensees and end users, other than physicians, (and copy the other Party) that such activities are not permitted and could expose such licensee and end
users to claims from the other Party or other Third Parties. 
 (e) Other GTS Developments and Further GTS Developments. Although
Ulthera does not have exclusive or other license rights to the Other GTS Developments or Further GTS Developments, other than pursuant to Section 2.1(c) with respect to the patents and patent applications in Exhibit E, Table E-2 and labeled
Outside Field GTS Patent Rights, the following rights are hereby granted to Ulthera: 
 (i) Licensors hereby grant to Ulthera and its
licensees a covenant-not-to-sue in the Field under the New GTS Developments and a covenant-not-to-sue for the Treatment of [***] under the Further GTS Developments; 

(ii) Upon the acquisition of Ulthera (whether of substantially of all of the stock or assets of Ulthera) by a Third Party (“Third Party
Acquirer”), the covenant-not-to-sue in the Field under the Other GTS Developments and the covenant-not-to-sue for the Treatment of [***] under the Further GTS Developments granted to Ulthera and its licensees under Section 2.1(e)(i) shall
convert to a non-exclusive, royalty-bearing, sublicenseable license under Licensors respective rights and interests in the New GTS Developments in the Field and Further GTS Developments for the Treatment of [***] to Ulthera (or Third Party Acquirer
if an asset acquisition) develop, have developed, use, make, have made, offer for sale, sell, have sold, import or otherwise commercially exploit Licensed Product(s) within the Field (Other GTS Developments) and for the Treatment of [***] (Further
GTS Developments) in the Territory, so long as the Third Party Acquirer agrees that it (and its sublicensees), shall not assert or bring a claim or cause of action based on the non-exclusive rights licensed under this Section 2.1(e)(ii) against
Licensors or any of their Affiliates or licensees. At any time following such acquisition of Ulthera by such Third Party Acquirer, Licensors may negotiate enhanced rights, e.g., exclusive rights or expanded fields of use, with the Third Party
Acquirer with respect to the non-exclusive rights in the Field set forth in this Section 2.1(e)(ii), or the Third Party Acquirer may elect to terminate in its sole discretion the non-exclusive license rights granted through written notification
to Licensors. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (f) Ulthera New Developments. Although Licensor does not have non-exclusive or other
license rights to any new developments or other Patents Rights of Ulthera for use outside the Field (other than the license to Ulthera Patent Rights in Section 3.5, which license shall be unaffected by this Section 2.1(f)) (hereinafter
“Ulthera New Developments”), the following rights are hereby granted to Licensor. Ulthera hereby grants to Licensors and their licensees a covenant-not-to-sue outside the Field under the Ulthera New Developments, provided that
(i) such Ulthera New Developments, excluding New Developments directed to the treatment of [***] outside the Field, were filed in a patent application filed [***], and (ii) Ulthera may terminate the rights set forth in Section 2.1(f)
at any time after three months following acquisition of GTS (whether of substantially of all of the stock or assets of GTS). For the sake of clarity, if Ulthera is acquired by a Third Party Acquirer, the Ulthera New Developments do not include any
of the intellectual property rights of the Third Party Acquirer. For clarity, any Ulthera New Developments directed to the treatment of [***] outside the Field, as of and up to the Effective Date, shall be subject to the covenant-not-to-sue of this
Section 2.1(f). 
 2.2 Patent Marking. Ulthera shall endeavor to properly mark any Licensed Products with the corresponding
patent number(s) from the applicable GTS Patent Rights in compliance with United States Code Title 35, Section 287(a), or with a patent pending status as appropriate. 

2.3 License Rights to Affiliates. 

(i) Ulthera shall have the right to extend all or any portion of the licenses granted herein to any of its Affiliates, upon the terms and
conditions of this Agreement, provided Ulthera or its Affiliates agree in writing to be responsible for the performance by such Affiliates of all of Ulthera’s obligations hereunder. 

(ii) Each Party agrees that it shall not attempt to circumvent any obligation or covenant under this Agreement by conveying rights to an
Affiliate. 
 2.4 Sublicense Rights. 

(a) Ulthera shall have the right to grant sublicenses to GTS Patent Rights within the Field to any Third Party. Ulthera will remain responsible
to Licensor for payment of all royalty payments due under this Agreement, whether or not such payments result from Net Sales by Ulthera or a sublicense, and all breaches of this Agreement by any such sublicensee, whether or not Ulthera can control
such sublicensee. 
 (b) Termination of this Agreement herein shall terminate all sublicenses, which Ulthera may have granted. Upon
termination of this Agreement, Licensors will enter into direct licenses with all parties that have received a sublicense from Ulthera of its rights under this Agreement on the same terms of this Agreement unless such sublicense parties elect to
terminate their respective sublicenses. Any 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
sublicense granted by Ulthera shall contain provisions corresponding to those of this Agreement respecting termination and the conditions of continuance of sublicenses. 

(c) Ulthera shall have the sole power to determine whether or not to grant sublicenses, the identity of sublicensees, and the royalty rates and
terms and conditions of such sublicenses; provided, however, that any sublicensee agrees to comply with all the terms of this Agreement to the extent applicable from the rights originally sublicensed to it by Ulthera. 

2.5 Expansion of the Scope of the Field. 

(a) Prior Option to Other Cosmetic Applications. Licensors acknowledge that as of the Effective Date of the Second Restated Agreement, Ulthera
has performed its obligations and made all required payments necessary to exercise the Option as set forth in 2.5(a)(i)-(ii) of the First Modification and thus retains the license granted to it for the Other Cosmetic Applications (excluding the
Targeted Treatment of [***]) within the Field. 
 (b) As of the Effective Date of the Second Restated Agreement, Licensee has exclusive
rights to the Targeted Treatment of [***]. To retain the exclusive rights to the Targeted Treatment of [***], Licensee has complied with Sections 2.5(b)(i) and (ii) below, and has additionally complied with the payment obligation in
Section 2.5(c) below. 
 (i) Ulthera initiated a development program for the Targeted Treatment of [***] to commence sometime before or
in the third quarter of 2012, and utilized GTS for Development Services on the front end of that program to help define the scope of the development, assess technology requirements and provide support on feasibility work. All efforts initially were
focused upon adding the ability to treat [***] into the existing Ulthera platform in order to leverage the growing installed base of Ulthera Systems worldwide; and 

(ii) As of the Effective Date, Licensors acknowledge that Ulthera has paid GTS $1,000,000 in Development Services for the Targeted Treatment
of [***], as set forth in Exhibit F. 
 (c) Ulthera’s obligations related to the Development Services for the Targeted Treatment of
[***] have been fulfilled subject to the requirements of this Agreement and prior Agreements, including Royalty Payments in 5.1. 
 (d) Field
for Treatment of [***]. 
 (i) As of the Effective Date, Licensors acknowledge that the Field has been expanded to include the Treatment of
[***], provided that Ulthera pay a $2,000,000 licensing fee to GTS. The parties agree to the following payment schedule: $200,000 upon the signing of this Agreement by both GTS and Ulthera; $100,000 per month in October, November and December 2013;

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
then $500,000 per quarter for Q1 of 2014, Q2 of 2014, and Q3 of 2014 (or later as mutually agreed upon by GTS and Ulthera), to be paid by the end of each time period, for a cumulative total
of $2,000,000. Upon completing payment of the cumulative total of $2,000,000, the parties agree that Ulthera shall retain the rights conveyed under Article 2 for the Field for the Treatment of [***] subject to the requirements of this Third Restated
Agreement, including Royalty Payments in 5.1. 
 (ii) Ulthera shall pay GTS the royalty payments as provided under Section 5.1[***] for
Licensed Products for the Treatment of [***]. 
 (iii) By [***], or as otherwise agreed upon by both parties, GTS and Ulthera will negotiate
in good faith, a development program for the Treatment of [***]. For the avoidance of doubt, as long as GTS and Ulthera negotiate a development program for the Treatment of [***] in good faith, 2.5(d)(iii) shall not be deeded to have been breached,
whether or not GTS and Ulthera ultimately agree to or implement a development program for the Treatment of [***]. 
 2.6 Rights to
MEEI Patent. Ulthera hereby grants to Licensors the exclusive and complete rights of Ulthera outside the Field under Ulthera’s respective rights and interests in the MEEI Patent Rights as set forth in the Ulthera-MEEI Agreement to research,
develop, have developed, make, have made, use, have used, import, export, distribute, sell. have sold, offer for sale, or otherwise exploit the products outside the Field, For clarity, the “MEEI Patent Rights” shall mean all Patent Rights
related to or resulting from [***]. Furthermore, Ulthera grants to Licensors all rights, remedies, and releases as set forth in the Ulthera-MEEI Agreement; however, if there is any conflict between the Ulthera-MEEI Agreement and this Agreement,
other than this Section 2.6, this Agreement supersedes the Ulthera-MEEI Agreement. 
 ARTICLE 3 

Development Services and Other Rights Transfer Provisions 

3.1 Provider of Development Services. Except as specifically provided herein, it is agreed that GTS, which may include the efforts of
Ardent Sound, shall provide Development Services to Ulthera under the following terms and conditions: 
 (a) Development Project. Ulthera
may, at its discretion, provide from time to time a written request to GTS for development activities related to the Field (the “Development Project”). Upon receipt of such a request for a Development Project, GTS shall then submit to
Ulthera in a timely manner (i) a specification for each requested Development Project, (ii) an estimate of the budget required for each requested Development Project (the “Development Budget”), wherein said Development Budget is
based on commercially reasonable costs and fees, (iii) the anticipated number of months required to complete the development of such Development Project (the “Development Period”), (iv) technical specifications related to the
Development Project (the “Specifications”), and (v) a schedule of providing deliverables and associated compensation adjustments for late delivery (collectively, the foregoing submission being

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the “Proposal”). The Proposal and any related agreements for Development Services shall be negotiated in good faith by the Parties. 

(b) Acceptance and Performance. Ulthera will have the right to modify the Proposal in good faith and Licensors will adopt the modifications.
Licensors will perform the Development Services in accordance with the agreed Proposal. If such Development Services are performed at a place other than Ulthera, GTS will permit Ulthera’s representatives to inspect the work from time to time as
deemed reasonably necessary by Ulthera and upon prior approval of GTS. GTS will keep Ulthera informed of the progress of the work through a report provided to Ulthera monthly or more frequently if reasonably requested. GTS will notify Ulthera
promptly if GTS’s and/or Ardent Sound’s performance of the Development Services falls behind the agreed schedule. In the event that Ulthera desires GTS, through the efforts of Ardent Sound, to undertake additional duties and
responsibilities to develop products outside the scope of Development Services, Ulthera and GTS shall negotiate a separate agreement for such additional duties and responsibilities. Licensors will perform the Development Services in compliance with
applicable law. Licensors will keep complete and accurate records of all activities conducted pursuant to the Development Services and all Work Product, and such records and Work Product will be considered the confidential information of Ulthera
under this Agreement. Licensors shall not subcontract their respective responsibilities under the Development Services without prior written consent of Ulthera. 

(c) Project Manager. The Ulthera Project Manager or designee shall generate progress meeting minutes from time to time, which reconcile
previous month(s) deliverables and projected GTS and Ardent Sound deliverables for the subsequent month(s) during the Development Period. 

3.2 Ownership of Intellectual Property Developed Through Development Services. Except as specifically provided herein, it is agreed that
the Work Product created in the course of the performance of the Development Services by GTS or Ardent Sound is to be the sole and exclusive property of Ulthera. 

(a) Assignment. Except as specifically provided herein, Licensors agree to assign and hereby assign all rights, title and interest in the Work
Product resulting from Development Services to Ulthera. Licensors will fully cooperate with Ulthera to enable Ulthera to perfect its rights, title and interest obtained hereunder, including executing and delivering all requested assignments and
other documents and providing good faith testimony by affidavit, declaration or other means. 
 (b) Copy Retention. GTS may retain one copy
of the Work Product for archival purposes only, all other copies of such property being subject to delivery to Ulthera by GTS upon request by Ulthera or upon completion or termination of the Development Services. 

(c) Restriction in Field. Licensors agree that during the Term they shall not commercially exploit in the Field for themselves or for any Third
Party the Work 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Product developed by GTS and/or Ardent Sound for Ulthera under this Agreement. Moreover, during the Term, Licensors shall not independently or with a Third Party pursue research or develop
technology, products, methods or components that are specifically designed for ultrasound therapy or treatment applications within the Field, and shall not independently or with a Third Party, apply, market or sell within the Field any technology,
products, methods or components that are specifically designed for ultrasound therapy or treatment applications, including without limitation any applications that are developed, marketed or sold in the Field in combination with ultrasound treatment
or therapy in a single device. For the avoidance of doubt, Licensors shall be permitted to independently pursue research and develop any technology, products, methods or components for ultrasound therapy or treatment applications in any field,
provided that Licensors will not use any funds or other resources provided by Ulthera to conduct such research and development, and Licensors will not conduct such research and development in a manner that limits the availability of Licensors’
personnel or development capacity and prevents the complete and timely performance of Development Services for Ulthera. Moreover, Licensors will notify Ulthera if any Third Party contacts either of Licensors to obtain or provide products or services
in the Field. Except as otherwise set forth herein, the restrictions set forth in this Section 3.2(c) can be terminated by GTS (i) at any time at the end of a twelve (12) month period commencing after the second year after a Change in
Control of Ulthera in which [***] during such twelve-month period, except if [***] during such twelve month period; (ii) with respect to the Licensed Products relating to Face and Neck Applications, upon Ulthera’s failure to pay GTS the
royalty payments as provided under Section 5.1(a) for Licensed Products for Face and Neck Applications; (iii) with respect to the Licensed Products relating to Other Cosmetic Applications, upon Ulthera’s failure to pay GTS the royalty
payments as provided under Section 5.1(a) for Licensed Products for Other Cosmetic Applications; (iv) with respect to the Licensed Products [***], upon Ulthera’s failure to pay GTS the royalty payments as provided under
Section 5.1(b) for Licensed Products for the [***]; or (v) with respect to the Licensed Products relating to [***], upon Ulthera’s failure to satisfy the requirement under Section 2.5(d) or upon Ulthera’s failure to pay GTS
the royalty payments as provided under Section 5.1(c) for Licensed Products for the [***]. 
 3.3 Know-How. Licensors will
deliver all new Know-How and to the extent reasonably feasible any new Work Product developed by GTS through Development Services to Ulthera on a quarterly basis or as can be reasonably delivered by GTS upon request by Ulthera from time to time.

 3.4 Activities Outside the Scope of this Agreement. Subject to Section 2.1. and 3.2, this Agreement does not limit, restrict
or prohibit GTS, Ardent Sound or its Affiliates from using the GTS Technology for activities outside the Field (e.g., in connection with any development services permitted under Section 3.2 and performed by GTS, Ardent Sound or its Affiliates
under this Agreement) (“Outside Activities”) or is intended to be construed to grant an interest in or license to such Outside Activities to Ulthera, or to any rights resulting therefrom, which shall be reserved solely by any of GTS,
Ardent Sound and its Affiliates and/or their respective Third Party licensees. For the avoidance of doubt, it is also understood and agreed by the Parties that Ardent 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Sound has developed and will continue to develop Diagnostic Imaging Applications and that GTS will continue to develop Imaging Therapeutic Applications that are available for commercial sale or
license to Third Parties, and that such Third Parties may desire to acquire and use such Diagnostic Imaging Applications and/or such Imaging Therapeutic Applications for any type of therapeutic process or treatment, and nothing herein shall be
deemed to limit or restrict Ardent Sound’s or GTS’ ability to design, develop, make and sell such Diagnostic Imaging Applications and/or Imaging Therapeutic Applications to Third Parties, provided that Licensors will not grant license
rights to such Third Parties under any GTS Technology in the Field. 
 3.5 Grantback of Ulthera Patent Rights to GTS. 

(a) Ulthera hereby grants to Licensors a royalty-free non-exclusive, sublicenseable license under the Ulthera Patent Rights and the Work
Product that are developed solely by GTS or Ardent Sound for Ulthera, or jointly by GTS, Ardent Sound and Ulthera (or any combination of two or more thereof), during the Term to develop, have developed, use, make, have made, offer for sale, sell,
have sold or import products outside the Field. For clarity, developments created by Ulthera alone or with a party other than GTS or Ardent Sound are Ulthera New Developments. Ulthera makes no representation regarding the Ulthera Patent Rights and
has no obligation to defend, indemnify or hold Licensors harmless in the event any claims, suits, proceedings, expenses, recoveries or damages arise out of, are based on, or are caused by any products, use, activity, or allegation of infringement of
any Ulthera Patent Rights. At Ulthera’s request, and to the extent commercially feasible, GTS shall endeavor to properly mark any products with the corresponding patent number(s) from the applicable Ulthera Patent Rights in compliance with
United States Code Title 35, Section 287(a), or with a patent pending status as appropriate. 
 (b) Other than the license rights
granted in Section 3.5(a) and the covenants granted in Section 2.1(f), Licensors shall have no license or other rights to any other Patent Rights of Ulthera, whether developed solely by Ulthera, or jointly with, or solely by, a Third Party
other than GTS or Ardent Sound or an Affiliate thereof. 
 ARTICLE 4 

Commercialization and Regulatory Activities 

4.1 Sales and Marketing. Ulthera will have the sole discretionary right to sell, offer for sale, contract, distribute, enter orders,
invoice, collect, and market the Licensed Products. 
 4.2 Clinical Trials. Ulthera shall assume all clinical costs associated with
any clinical program. 
 4.3 Regulatory. Ulthera shall be responsible for filing for regulatory approval for the Licensed Product in
the United States and in all countries throughout the World, as determined solely by Ulthera. At Ulthera’s request, GTS shall provide 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Ulthera for its use in obtaining regulatory approvals for the Licensed Product copies of the following items that pertain to the Licensed Products: all data, including, but not limited to,
results and related information from clinical trials (if any), physical test data, biocompatability data, animal data, bench testing and stability data. 

4.4 Commercialization Discretion. The development, marketing, sale or other commercial exploitation (collectively, the “Commercial
Exploitation”) of the Licensed Products in the Territory shall be exercised by Ulthera in accordance with its own business judgment and in its sole and absolute discretion. 

4.5 Adverse Event Reporting. Except where precluded by confidentiality or other obligations to Third Parties, each of the Parties will
notify the others promptly (but no later than five (5) business days after such Party becomes aware) of any serious, unexpected adverse event information relating to any product of the notifying Party (whether or not related to a Licensed
Product) for any indication, including without limitation information from human clinical, in vitro or animal studies suggesting a significant hazard to humans. For purposes of this Section 4.5, the phrase “serious, unexpected adverse
event information” includes, without limitation, information relating to any experience that (a) suggests a significant hazard, contraindication, side effect or precaution, (b) is fatal or life threatening, (c) is permanently
disabling, (d) requires or prolongs hospitalization, (e) involves a congenital anomaly, cancer or overdose, (f) is one not identified in nature, specificity, severity or frequency in the current investigator brochure or the approved
product labeling for such product, or (g) includes findings from tests in laboratory animals that suggest a significant safety risk to humans, including without limitation reports of mutagenicity, teratogenicity or carcinogenicity. 

ARTICLE 5 
 Payments; Records;
Audits 
 5.1 Royalty Payments. 

(a) Licensed Products for Face and Neck Applications and Other Cosmetics Applications. In consideration for the license(s) granted herein
relating to Face and Neck Applications and Other Cosmetics Applications [***], Ulthera shall pay GTS on a quarterly basis a royalty payment of [***] percent ([***]%) on Net Sales of each Licensed Product relating to Face and Neck Applications
and Other Cosmetics Applications [***] 5.1(b)-(c) [***]; provided, however, that Ulthera’s obligation to pay any such royalties shall terminate, in any case, when all the GTS Patent Rights expire. 

(b) Licensed Products for [***]. In consideration for the license(s) granted herein [***], Ulthera shall pay GTS on a quarterly basis:
(i) an earned royalty of [***] percent ([***]%) on Net Sales of each Licensed Product [***] for the [***] following the First Commercial Sale of a Licensed Product [***] (the “[***]”); (ii) an earned royalty of [***] percent
([***]%) on Net Sales of each Licensed Product [***] for the period between [***] to [***] following the [***] (the “[***]”); and (iii) [***] percent ([***]%) on Net Sales of each Licensed Product [***] for the period after [***] and
beyond the [***]”, corresponding to the [***] after the [***]); provided, however, that Ulthera’s obligation to 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
pay any such royalties shall terminate, in any case, when all the GTS Patent Rights expire. 

(c) Licensed Products for [***]. In consideration for the license(s) granted herein [***], upon Ulthera satisfying all the requirements under
Section 2.5(d), Ulthera shall pay GTS on a quarterly basis: (i) an earned royalty of [***] percent ([***]%) on Net Sales of each [***] that [***] falls under the definition of a Licensed Product (hereinafter “[***]”) for the
[***] following the First Commercial Sale of a Licensed Product [***] (the “[***]”); (ii) an earned royalty of [***] percent ([***]%) on Net Sales of each [***] for the period between [***] to [***] following the [***] (the
“[***]”); and (iii) [***] percent ([***]%) on Net Sales of each [***] for the period after [***] and beyond the [***]”, corresponding to the [***] after the [***]); provided, however, that Ulthera’s obligation to pay any
such royalties shall terminate, in any case, when all the GTS Patent Rights expire. In consideration for the license(s) granted herein [***], upon Ulthera satisfying all the requirements under Section 2.5(d), Ulthera shall pay GTS on a
quarterly basis an earned royalty on [***] of a percent to be determined, but not less than [***] percent ([***]%) in connection with the negotiation in good faith of the development agreement specified in Section 2.5(d)(iii). 

(d) Non-Exclusive License for New GTS Developments and Further GTS Developments. In consideration for any license(s) granted to a Third Party
Acquirer as set forth in Section 2.1(e)(ii), any Third Party Acquirer shall pay GTS on a quarterly basis an additional royalty payment of [***] percent ([***]%) on Net Sales of each Licensed Product (which are cumulative and in addition to any
other royalty payments already due under Sections 5.1(a) and (b)) relating to Face and Neck Applications, Other Cosmetics Applications, [***] that is covered by a Valid Claim of any Patent Rights within the New GTS Developments. In consideration for
any license(s) granted to a Third Party Acquirer as set forth in Section 2.1(e)(ii), any Third Party Acquirer shall pay GTS on a quarterly basis a further additional royalty payment of [***] percent ([***]%) on Net Sales of each Licensed
Product (which are cumulative and in addition to any all royalty payments already due under Sections 5.1(a) and (b) and the [***] percent due on Net Sales related to New GTS Developments) relating to Face and Neck Applications, Other Cosmetics
Applications, [***] that is covered by a Valid Claim of any Patent Rights within the Further GTS Developments. These non-exclusive licenses to Patent Rights within the New GTS Developments and the Further GTS Developments are provided, however, that
such Third Party Acquirers obligation to pay any such cumulative and additional [***] percent ([***]%) royalties shall terminate, in any case, if such Third Party Acquirer terminates the non-exclusive license rights granted in
Section 2.1(e)(ii), or when all the Patent Rights for the New GTS Developments and Further GTS Developments expire. 
 (e) The royalty
payment obligations provided under Section 5.1(a)-(d) are subject to the following: 
 (i) Earned royalties shall be payable on
Net Sales of any Licensed Product that is manufactured, used, imported or sold in only those countries having an issued patent with a Valid Claim and shall be paid to GTS. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (ii) Multiple earned royalties shall not be payable due to any Licensed Product being covered by
more than one of the GTS Patents Rights, except as set forth in Section 5.1(d). The additional royalties pursuant to Section 5.1(d) shall be [***] with respect to the Patent Rights within the New GTS Developments and the Further GTS
Developments. 
 (iii) Ulthera shall have no annual minimum royalty payment obligations. 

(iv) The Parties agree that Ulthera shall owe no royalties to Ardent Sound, and any payments owed to Ardent Sound by GTS pursuant to any
license or other arrangement between GTS and Ardent Sound shall be paid by GTS. 
 5.2 Payment; Reports. Royalty payments shall be
calculated and reported for each calendar quarter. All royalty payments due to GTS under this Agreement shall be paid within forty-five (45) calendar days of the end of each calendar quarter, unless otherwise specifically provided herein. Each
payment of royalties shall be accompanied by a written report in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, without limitation, Net Sales, the royalties payable in United States dollars, the
method used to calculate the royalty and the exchange rates used. 
 5.3 Exchange Rate; Manner and Place of Payment. All payments
hereunder shall be payable in United States dollars. With respect to each quarter, for countries other than the United States, whenever conversion of payments from any foreign currency shall be required, such conversion shall be made at the rate of
exchange reported in The Wall Street Journal on the last business day of the applicable reporting period. 
 5.4 Records and Audits.
During the Term, and for a period of two years thereafter, Ulthera shall keep complete and accurate records in sufficient detail to permit GTS to confirm the accuracy of all payments and reports due hereunder. GTS shall have the right to cause an
independent, certified public accountant reasonably acceptable to Ulthera and subject to terms of a confidentiality agreement to audit such records to confirm royalty payments for the preceding year. Such audits may be exercised during normal
business hours no more than once in any twelve (12) month period upon at least thirty (30) calendar days’ prior written notice to Ulthera. GTS shall bear the full cost of such audit unless such audit discloses an underpayment by more
than five percent (5%) of the amount due under this Agreement. In such case, Ulthera shall bear the full cost of such audit and shall pay any underpayment with interest at the rate of five percent (5%) compounded annually from the date due until the
date Ulthera actually pays GTS. Any dispute regarding any payments due hereunder shall be subject to the dispute resolution procedures set forth in Article 9. 

ARTICLE 6 
 Representations and
Disclaimer of Warranties 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 6.1 All GTS Technology Provided to Ulthera in Accordance With This Agreement Is Provided
“As Is”. NOTHING IN THIS AGREEMENT SHALL BE DEEMED TO BE A REPRESENTATION OR WARRANTY BY LICENSORS OF THE VALIDITY OF ANY OF THE GTS PATENT RIGHTS OR THE ACCURACY, COMPLETENESS, SAFETY OR USEFULNESS FOR ANY PURPOSE, OF ANY GTS TECHNOLOGY
LICENSED BY GTS TO ULTHERA. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, AND EXCEPT FOR ANY INJURY, LOSSES OR DAMAGES DIRECTLY CAUSED BY A MATERIAL BREACH BY LICENSORS OF THE REPRESENTATIONS AND WARRANTIES UNDER ARTICLE 6 OF THIS AGREEMENT OR ANY
OBLIGATIONS ARISING OUT OF ARTICLE 7, OR BY THE NEGLIGENCE OR WILLFUL MISCONDUCT OF LICENSORS, LICENSORS SHALL HAVE NO LIABILITY WHATSOEVER TO ULTHERA OR ANY OTHER PERSON FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE OF ANY KIND OR NATURE,
SUSTAINED BY, OR ANY DAMAGE ASSESSED OR ASSERTED AGAINST, OR ANY OTHER LIABILITY OF ANY OTHER PERSON, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM, THE PRODUCTION, USE OR SALE OF ANY LICENSED PRODUCT, OR THE PRACTICE OF THE GTS TECHNOLOGY
AND ULTHERA SHALL HOLD LICENSORS, THEIR AFFILIATES, OFFICERS, EMPLOYEES, OR AGENTS, HARMLESS IN THE EVENT ULTHERA, OR ITS OFFICERS, EMPLOYEES, OR AGENTS IS HELD LIABLE. 

6.2 EXCEPT AS SPECIFICALLY SET FORTH HEREIN, LICENSORS MAKE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, TO ULTHERA, INCLUDING,
WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND/OR NON-INFRINGEMENT. 
 6.3 NEITHER
PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE SUCCESS OF THE DEVELOPMENT OR THE COMMERCIAL EXPLOITATION OF ANY LICENSED PRODUCT. 

6.4 LICENSORS REPRESENT AND WARRANT AS FOLLOWS: (A) EXHIBITS A, B, AND C REPRESENT A COMPLETE AND ACCURATE LIST OF ALL PATENT
RIGHTS OWNED, OR LICENSED TO OR OTHERWISE CONTROLLED BY LICENSORS AND THEIR AFFILIATES, UP TO AND AS OF THE EFFECTIVE DATE, (B) LICENSORS HAVE NOT GRANTED TO ANY THIRD PARTY ANY INTELLECTUAL PROPERTY RIGHTS IN THE FIELD, (C) THE GRANTING
OF THE LICENSE TO THE GTS TECHNOLOGY WILL NOT VIOLATE ANY PRIOR AGREEMENTS BETWEEN GTS OR ARDENT SOUND AND THIRD PARTIES OR ANY PROVISION OF LAW, STATUTE, RULE OR REGULATION, (D) NO OTHER PERSON OR ENTITY HAS ANY RIGHT, TITLE OR INTEREST IN OR
TO THE GTS TECHNOLOGY THAT COULD INTERFERE WITH THE GRANTING OF THE LICENSE CONTEMPLATED HEREIN, (E) EXCEPT FOR THE ARDENT-GTS AGREEMENT, LICENSORS HAVE NOT GRANTED ANY LICENSE RIGHTS IN THE GTS TECHNOLOGY IN THE FIELD TO ANY THIRD PARTY, AND
(F) THE LICENSED SOFTWARE IS OWNED BY LICENSORS, OR LICENSED FROM THIRD PARTIES, WITHOUT ANY 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
REQUIREMENT TO PUBLICLY DISCLOSE ANY SUCH SOFTWARE AND WITHOUT THE NEED TO OBTAIN CONSENT FROM SUCH THIRD PARTIES TO LICENSE SUCH SOFTWARE TO ULTHERA. 

ARTICLE 7 
 Indemnification

 In order to distribute among themselves the responsibility for claims arising out of this Agreement, and except as otherwise
specifically provided for herein, the Parties agree as follows: 
 7.1 Indemnification by GTS. GTS agrees to defend and indemnify and
hold Ulthera harmless against any and all Third Party claims, suits, proceedings, expenses, recoveries and damages including court costs and reasonable attorneys fees and expenses, arising out of, based on, or caused by (a) the breach by GTS of
any material representation or warranty contained in this Agreement, in each case except to the extent that such claims, suits, proceedings, expenses, recoveries or damages arise from or are aggravated by acts of or failure to act by Ulthera, or
(b) GTS misappropriation or wrongful use of a trade secret or other proprietary right (excluding Patent Rights); provided that (i) Ulthera shall provide GTS with reasonably prompt written notice of any claim or action for which it seeks
indemnification under this Section 7.1; (ii) GTS shall have sole control of the defense and settlement of any such claim or action; (iii) Ulthera shall reasonably cooperate and provide reasonable assistance in connection with the
defense and settlement of any such claim or action; and (iv) except for actions arising from or caused by the willful, intentional, or grossly negligent acts on the part of GTS, any such expenses, recoveries, damages, costs and fees are limited
to the amount of any payments received by GTS under this Agreement. GTS will not enter a settlement involving payment of money by Ulthera without prior written consent by Ulthera. 

7.2 No Indemnification for Intellectual Property Infringement. Due to the uncertainty of the Intellectual Property rights of Third
Parties, GTS has no obligation to defend, indemnify or hold Ulthera harmless in the event any claims, suits, proceedings, expenses, recoveries or damages arise out of, are based on, or are caused by any allegation of infringement of any Intellectual
Property Rights of any Third Party resulting from the development, manufacture, use, offer for sale, or sale of Licensed Products or any other products produced under the Development Services. However, in the event any such allegation of
infringement occurs, GTS agrees to (a) cooperate with Ulthera in the defense of Ulthera with respect to the alleged infringement, and (b) work with Ulthera to replace or modify the alleged infringing product during the further performance
of Development Services until Ulthera is satisfied that such replaced or modified product is outside the scope of any such allegation of infringement. Moreover, in the event that a license from any Third Party is

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
required by Ulthera in order to make, have made, have used, sell, offer to sell, have sold or import and have imported any particular Licensed Product without infringing a Patent Right of a Third
Party, then any royalty payment which Ulthera is obligated to pay to GTS under Section 5.1 shall be reduced [***] for each [***] of additional royalty obligations to Third Parties in a royalty-bearing license, or by [***] of the royalties or
other payments payable by Ulthera to Third Parties pursuant to any additional Third Party agreement in a pre-paid or other lump sum payment agreement, provided, however, that in no event will the total royalty payments payable to GTS under this
Agreement be reduced to less than [***] of the royalties otherwise due to GTS under this Agreement. 
 7.3 Indemnification by Ulthera.
Ulthera agrees to defend and indemnify and hold GTS and Ardent Sound harmless against any and all Third Party claims, suits, proceedings, expenses, recoveries, and damages including court costs and reasonable attorneys fees and expenses, in
connection with any of the Licensed Product sold or disposed for value by Ulthera or its Affiliates arising out of, based on, or caused by (a) the development, manufacture, the storage, sale, shipment, promotion or distribution of the Licensed
Product by Ulthera or its Affiliates, or (b) the breach by Ulthera of any material representation or warranty contained in this Agreement, in each case except to the extent that such claims, suits, proceedings, expenses, recoveries or damages
arise from acts of or failure to act by GTS and Ardent Sound; provided that (i) GTS and/or Ardent Sound shall provide Ulthera with prompt written notice of any claim or action for which it seeks indemnification under this Section 7.3 and
of any invitation to license provided by such Third Party; (ii) Ulthera shall have sole control of the defense and settlement of any such claim or action; and (iii) GTS and/or Ardent Sound shall reasonably cooperate and provide reasonable
assistance in connection with the defense and settlement of any such claim or action. Ulthera will not enter a settlement involving payment of money by GTS and/or Ardent Sound without prior written consent by GTS and/or Ardent Sound, which consent
shall not be unreasonably withheld. 
 7.4 Sole Remedy. The indemnification provisions set forth in this Agreement constitute the sole
and exclusive remedies of the Parties for any and all Third Party claims, suits, proceedings, expenses, recoveries, and damages in respect of this Agreement. 

7.5 Limitations on Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY CONSEQUENTIAL, EXEMPLARY, INCIDENTAL, SPECIAL OR
PUNITIVE DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER (INCLUDING, WITHOUT LIMITATION, LOST PROFITS), REGARDLESS OF WHETHER A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE OR WHETHER SUCH
DAMAGES ARE REASONABLY FORESEEABLE. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL GTS BE LIABLE FOR DAMAGES IN EXCESS OF THE SUM OF AMOUNTS GTS HAS RECEIVED FROM ULTHERA UNDER THE TERMS OF THIS AGREEMENT. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ARTICLE 8 

TERM AND TERMINATION 

8.1 Term. The “Term” of this Agreement shall commence as of the Effective Date of this Agreement and shall continue until the
last of the GTS Patent Rights expire or otherwise terminated in accordance with this Article 8. 
 8.2 Ulthera Termination For
Convenience. Ulthera may terminate this Agreement for any reason upon ninety (90) calendar days’ prior written notice to GTS and Ardent Sound. 

8.3 Ulthera Termination for Event of Default by Licensors. Subject to Ulthera’s compliance with the provisions in Section 8.6,
Ulthera may terminate this Agreement upon the occurrence of any one or more of the following acts, events or occurrences, each of which shall constitute an “Event of Default” under this Agreement: 

(a) GTS or Ardent Sound becomes the subject of a Bankruptcy Event; 

(b) GTS or Ardent Sound violates the provisions of Section 3.2(c) of this Agreement; 

(c) GTS or Ardent Sound commits any other material breach of this Agreement; or 

(d) in the event of a Change in Control of GTS or Ardent Sound, and such Change in Control involves (i) a Competitor (as defined below),
(ii) a Third Party which does not have the financial, production or other resources necessary for it to meet all of the obligations of the Party being replaced under this Agreement, or (iii) a Third Party who does not agree to be bound by
the obligations imposed on Licensors under this Agreement. For purposes of this Agreement, a “Competitor” shall mean any person or entity that is engaged in the business of developing or commercially exploiting products within the Field.

 8.4 GTS Termination for Event of Default by Ulthera. Subject to GTS’ compliance with the provisions of Section 8.6, GTS
may upon the occurrence of any one or more of the following acts, events or occurrences, each of which shall constitute an “Event of Default” under this Agreement: 

(a) Ulthera becomes the subject of a Bankruptcy Event; 

(b) Ulthera fails to make timely payments as required herein; or 

(c) Ulthera, its Affiliates, or any sublicense commits any other material breach of this Agreement. 

8.5 Termination Rights upon an Event of Default. Upon the occurrence of an Event of Default under Sections 8.4 or 8.5 of this Agreement
by one of the Parties, 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
(being referred to as the “Defaulting Party”), the non-defaulting Party in its sole discretion may terminate this Agreement so long as such Event of Default is not cured by the
Defaulting Party within forty-five (45) calendar days from receipt of written notice, subject to those insolvency rights under Section 8.8, if applicable. The non-Defaulting Party may provide its written consent to such Event of Default,
such consent not to prejudice any future termination of this Agreement based on another occurrence of such Event of Default. Notwithstanding the preceding, from the date a Party notifies the other Party that it wishes to commence a proceeding in
accordance with the dispute resolution procedures set forth in Article 9 until such proceeding has been concluded, the running of the time period referred to in this Section 8.6 for curing a breach shall be suspended with respect to the subject
matter of the dispute, claim or controversy. If Ulthera alleges an Event of Default by GTS, [***] until such alleged Event of Default is adjudicated by binding arbitration pursuant to Section 9.1, so long as [***] three (3) months. If the
arbitrator declines to find such an Event of Default, Ulthera will [***]. If the arbitrator determines an Event of Default exists, Ulthera may terminate this Agreement pursuant to Section 8.7(c), or allow GTS additional time to cure. The
parties will act in good faith to obtain an arbitration decision prior to three (3) months from the date that a non-defaulting party notifies a Defaulting Party in writing that the non-defaulting party wishes to commence arbitration. If the
arbitration process exceeds three (3) months, Ulthera will [***] if the arbitrator determines default. 
 8.6 Effects of
Termination 
 (a) Effect of Ulthera’s Termination for Convenience. In the event Ulthera terminates this Agreement in
accordance with Section 8.2, all licenses to any GTS Patent Rights granted herein shall terminate and Ulthera agrees to grant to GTS, at GTS’s sole discretion, a royalty-free, nonexclusive, transferable, sublicenseable, license under all
Ulthera Patent Rights and the Work Product that are developed solely by GTS or Ardent Sound for Ulthera, or jointly by GTS, Ardent Sound and Ulthera (or any combination thereof), covering all inventions conceived of and reduced to practice in the
course of the Development Services under this Agreement during the Term naming employees of GTS or Ardent Sound as inventors to develop, have developed, use, make, have made, offer for sale, sell, have sold and import products or processes, but for
the license granted herein would infringe at least one Valid Claim of any such Ulthera Patent Rights. 
 (b) Effect of Ulthera’s
Termination for Event of Default by Licensors. In the event this Agreement is terminated by Ulthera in accordance with Section 8.3, Ulthera may elect to retain the licenses granted to it under Section 2.1 of this Agreement, so long as
Ulthera continues its obligation to make royalty payments under this Agreement, such royalty payments being reduced by [***] percent ([***]%) from the effective rates under Section 5.1(a) and in which case Licensors agree to continue their
respective obligations under Sections 2, 3.2 and 3.3 of this Agreement. The proceeding sentence notwithstanding, in no event will the total royalty payments payable to GTS under this Section 8.6(b) be reduced to less than [***] percent ([***]%)
of the royalties otherwise due to GTS just prior to termination of this Agreement. In the 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
event this Agreement is terminated by Ulthera in accordance with Section 8.3 and Ulthera elects not to retain the licenses granted to it under Section 2 of this Agreement, then all GTS
Patent Rights granted herein and Licensors’ obligations under Section 3.2(c) shall terminate. In any event, Ulthera agrees to grant to GTS, at GTS’s sole discretion, a royalty-free, nonexclusive, transferable, sublicenseable, license
under all Ulthera Patent Rights and the Work Product outside the Field that are developed solely by GTS or Ardent Sound for Ulthera, or jointly by GTS, Ardent Sound and Ulthera (or any combination thereof), covering all inventions conceived of and
reduced to practice in the course of the Development Services under this Agreement during the Term naming employees of GTS or Ardent Sound as inventors to develop, have developed, use, make, have made, offer for sale, sell, have sold and import
products or processes, but for the license granted herein would infringe at least one Valid Claim of any such Ulthera Patent Rights. All other obligations shall terminate, subject to Section 8.11. 

(c) Effect of GTS’ Termination for Event of Default by Ulthera. In the event this Agreement is terminated by GTS in accordance with
Sections 8.4 and 8.5, all licenses to any GTS Patent Rights granted herein shall terminate, and Ulthera agrees to grant to GTS, at GTS’s sole discretion, a royalty-free, nonexclusive, transferable, sublicenseable, license under all Ulthera
Patent Rights and the Work Product that are developed solely by GTS or Ardent Sound for Ulthera, or jointly by GTS, Ardent Sound and Ulthera (or any combination thereof), covering all inventions conceived of and reduced to practice in the course of
the Development Services under this Agreement during the Term naming employees of GTS or Ardent Sound as inventors to develop, have developed, use, make, have made, offer for sale, sell, have sold and import products or processes, but for the
license granted herein would infringe at least one Valid Claim of any such Ulthera Patent Rights. 
 8.7 Force Majeure Events. If a
Party is prevented from performing any of its obligations hereunder due to any cause which is beyond the non-performing Party’s reasonable control, including, without limitation, fire, explosion, flood, or other acts of God; acts, regulations,
or laws of any government; war or civil commotion; strike, lock-out or labor disturbances; or failure of public utilities or common carriers (a “Force Majeure Event”), such non-performing Party shall not be liable for breach of this
Agreement with respect to such non-performance to the extent such non-performance is due to a Force Majeure Event. Such non-performance will be excused for three months or as long as such event shall be continuing (whichever period is shorter),
provided that the non-performing Party gives prompt written notice to the other Party of the Force Majeure Event. Such non-performing Party shall exercise all reasonable efforts to eliminate the Force Majeure Event and to resume performance of its
affected obligations as soon as practicable. Should the event of Force Majeure continue unabated for a period of sixty (60) days or more, the Parties shall enter into good faith discussions with a view to alleviating its affects or to agreeing
upon such alternative arrangements as may be fair and reasonable having regard to the circumstances prevailing at that time. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 8.8 Rights upon Insolvency. All rights and licenses granted under or pursuant to this
Agreement by Licensors to Ulthera are for all purposes of Article 365(n) of Title 11, U.S. Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined in the Bankruptcy Code. The Parties agree that
Ulthera, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. If this Agreement is rejected as provided in the Bankruptcy Code and Ulthera elects to retain
its rights hereunder as provided in Bankruptcy Code, Section 365(n) then Licensors (in any capacity, including debtor-in-possession) and their respective successors and assigns (including, without limitation, any trustee in bankruptcy) shall
provide or cause to be provided to Ulthera access to all such intellectual property (and any embodiments of intellectual property) in the Field held by or in the control of Licensors and such successors and assigns immediately upon Ulthera’s
written request therefore. The Parties agree that “embodiments” of intellectual property hereunder include, without limitation, data, software and other works of authorship, processes, techniques, procedures, compositions, devices,
methods, formulas, protocols and information, including, without limitation, all electrical, mechanical, chemical, biochemical, toxicological and scientific research information. All rights, powers and remedies of Ulthera provided under this
Section 8.9 are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including, without limitation, the Bankruptcy Code) in the event of any such commencement of
a bankruptcy proceeding by or against Licensors. Ulthera, in addition to the rights, powers and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or
hereafter exist at law or in equity (including the Bankruptcy Code) in such event. 
 8.9 Remedies Cumulative. Any termination by
Ulthera under Section 8.4 or by GTS under Section 8.5 above will be in addition to, and not in substitution for or a condition to, the pursuit of any other remedies available to such Party under this Agreement or in law or equity. Without
limiting the foregoing, in the event of a material breach by either Party of this Agreement, subject to Section 7.5, the Party that is not the breaching Party, without exercising any right of termination otherwise available to it, may pursue
its remedies for damages or other relief under the dispute resolution procedures set forth in Article 9. 
 8.10 Return of Confidential
Information. Upon termination of this Agreement, each Party will promptly return to the other Party, delete or destroy all relevant records and materials in such Party’s possession or control containing Confidential Information of the other
Party. 
 8.11 Survival of Certain Obligations. Expiration or termination of the Agreement will not relieve the Parties of any
obligation accruing before such expiration or termination. The following provisions of this Agreement will survive the expiration or termination of the Agreement: Articles 6 (Representations and Warranties), 7 (Indemnification), 8 (Term and
Termination), 9 (Dispute Resolution) and 11 (Miscellaneous) and Section 2.4(b) (Sublicense Rights); if Ulthera has elected to retain 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the licenses granted to it under Section 8.7(c), Section 3.2(c) (Restriction in Field); and, until the GTS Patent Rights have expired, Sections 5.1 (Royalty Payments), 5.2 (Payment;
Reports), 5.3 (Exchange Rate; Manner and Place of Payment), and 5.4 (Records and Audits). Except as set forth in this Section 8.11, upon termination or expiration of this Agreement, all other rights and obligations under this Agreement shall
then be null and void and have no further force and effect. Any expiration or early termination of this Agreement will be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement before termination.

 ARTICLE 9 
 Dispute
Resolution 
 9.1 Any controversy or claim arising out of or relating to this Agreement shall be resolved by binding arbitration
before a single arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) then pertaining (available at www.adr.org), except where those rules conflict with this provision, in which case
this provision controls. Any court with jurisdiction shall enforce this clause and enter judgment on any award. The arbitrator shall be selected within twenty (20) business days from commencement of the arbitration from the AAA’s National
Roster of Arbitrators pursuant to agreement or through selection procedures administered by the AAA. Within forty-five (45) days of initiation of arbitration, the Parties shall reach agreement upon and thereafter follow procedures, including
limits on discovery, assuring that the arbitration will be concluded and the award rendered within no more than eight (8) months from selection of the arbitrator or, failing agreement, procedures meeting such time limits will be designed by the
AAA and adhered to by the Parties. The arbitration shall be held in Phoenix, Arizona and the arbitrator shall apply the substantive law of Arizona or federal law as appropriate, except that the interpretation and enforcement of this arbitration
provision shall be governed by the Federal Arbitration Act. Prior to commencement of arbitration, emergency relief is available from any court to avoid irreparable harm. The arbitrator shall not award either party punitive, exemplary, multiplied or
consequential damages, or attorney’s fees or costs. 
 9.2 Prior to commencement of arbitration, the Parties must attempt to
mediate their dispute using a professional mediator from AAA, the CPR Institute for Dispute Resolution, or like organization selected by agreement or, absent agreement, through selection procedures administered by the AAA. Within a period of
forty-five (45) calendar days after the request for mediation, the Parties agree to convene with the mediator, with business representatives present, for at least one session to attempt to resolve the matter. In no event will mediation delay
commencement of the arbitration for more than forty-five (45) calendar days absent agreement of the Parties or interfere with the availability of emergency relief. 

9.3 In the event that the Dispute Resolution under Section 9.1 is unsuccessful in that the adjudicated breaching party continues to
breach the Agreement, the prevailing party may bring an action in any state or federal court of 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
competent jurisdiction and shall be entitled to any damages awarded, court costs, reasonable attorneys’ fees, expert witness fees and legal expenses as may be fixed by said court. Both
parties acknowledge that there will be no adequate remedy at law for its failure to comply with the terms of this Agreement. Accordingly, in the event a party fails to comply therewith, the non-breaching party shall have the right to have any breach
of this Agreement remedied by equitable relief by way of a temporary restraining order, preliminary injunction, permanent injunction, and such other alternative relief as may be appropriate. 

ARTICLE 10 
 Prosecution and
Maintenance of Patent Rights 
 10.1 Handling of Ulthera Patent Rights. 

(a) Ulthera shall, at its own expense and by counsel of its own choice, file, prosecute and maintain all patent applications and patents within
the Ulthera Patent Rights, including filing, prosecuting and maintaining both United States and foreign patent applications and patents in both the United States and in countries, as determined solely by Ulthera. 

(b) As to any patent applications or issued patents within the Ulthera Patent Rights with respect to which Ulthera determines not to respond to
any Office Action from a U.S. or foreign patent office or otherwise continue prosecution that as a consequence of not responding would result in irrevocable abandonment of the subject matter of the application, or determines not to pay any
maintenance or annuity fee for such patent applications or any patents, Ulthera shall offer to GTS the ability to continue, at GTS’s expense, with such prosecution or make such maintenance or annuity fee payments at least thirty
(30) calendar days prior to any final deadline for a response or payments, including the execution of any documents necessary for GTS to continue such prosecution or pay such maintenance or annuity fees. Ulthera further agree that it will
promptly execute any powers or attorney to any such patents and applications to Licensors upon request by Licensors, and Licensors will have the full right to prosecute any such applications, to file and prosecute new patent application claiming
priority to such application, and to pay such maintenance fees in Licensors’ sole discretion, and that any license granted in Section 3.5 to such patent or patent application shall become permanent and non-revocable, irrespective of rights
upon termination as set forth in Article 8. 
 (c) Upon written request, Ulthera agrees to provide GTS and its counsel with copies of all
correspondence to and from the patent offices related to the pending patent applications and future patent applications within Ulthera Patent Rights that are licensed back to GTS under Section 3.5(a). 

10.2 Handling of GTS Patent Rights Prosecuted by GTS. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (a) Except for those applications and patents identified as “Ulthera Prosecuted” on
Exhibit A, Licensors shall, at their own expense and by counsel of their own choice, file, prosecute and maintain all patent applications and patents within the GTS Patent Rights, including filing, prosecuting and maintaining foreign patent
applications and patents in countries, as determined solely by Licensors; provided, however, that Licensors will provide a copy to Ulthera of all office actions and all responses to office actions, and to any continuations and other divisional or
continuing patent applications in sufficient time prior to filing the same to allow Ulthera to review the office action and proposed filing and provide comments, and Licensors will consider all comments and claims provided by Ulthera and will
reasonably include such comments and claims in the filing. GTS shall endeavor to provide such office actions to Ulthera within one-month of receipt by a patent office, and shall provide a draft response to Ulthera at least two weeks prior to any
deadline for filing such response. Moreover, Licensors will not knowingly make any statements or omissions or take any other action during prosecution or enforcement of any GTS Patent Rights or Ulthera Patent Rights which admits or concedes that any
of such Patent Rights is invalid or unenforceable, or which adversely affects or limits the scope of any claims in such Patent Rights unless necessary to overcome prior art other than the GTS Patent Rights, without Ulthera’s prior written
consent. 
 (b) To the extent that Licensors determine with respect to any GTS Patent Rights not to respond to any office action from a U.S.
or foreign patent office or otherwise continue prosecution that as a consequence of not responding would result in irrevocable abandonment of the subject matter in a pending application, or determine not to pay any maintenance or annuity fee for
such patent application or any patents, or determine not to file a continuation or divisional application with respect to the patent application prior to its issuance, or file or validate in any foreign country, Licensors shall, as applicable, offer
to Ulthera the ability to continue, at Ulthera’s expense, prosecuting and maintaining such application or patent at least thirty (30) calendar days prior to the final deadline for a filing, validation, response or payments, including the
execution of any documents necessary for Ulthera to continue such prosecution, pay such maintenance or annuity fees, file or validate such applications. Licensors further agree that they will promptly grant powers of attorney in and to any such
patents and applications to Ulthera upon request by Ulthera, and Ulthera will have the full right to prosecute any such applications, to file and prosecute new patent application claiming priority to such application, and to pay such maintenance
fees in its sole discretion. It being understood that Ulthera will thereafter owe no further royalty to GTS for Net Sales of Licensed Products to the extent covered by such patent or patent application, and that any license granted in
Section 2.1(a) to such patent or patent application shall become permanent and non-revocable, irrespective of rights upon termination as set forth in Article 8. 

10.3 Handling of GTS Patent Rights Prosecuted by Ulthera 

(a) For those applications and patents identified as “Ulthera Prosecuted” on Exhibit A, the control and responsibility for
maintenance and 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
prosecution is transferred to Ulthera, pursuant to the terms of the Letter Agreement, along with the fees and costs associated with this prosecution only as incurred by Ulthera or its counsel
(and up to [***] per response to office action or new continuation claim set to allow for assessment and consultation by GTS, not to exceed [***] per month, unless Ulthera specifically requests and authorizes in writing, with a proposal, for
additional consultation from GTS). Such fees shall be billed to Ulthera with sufficient detail to identify the matter for which consultation (by application number) was provided, the type of work performed, and the consultation time incurred. For
the avoidance of doubt, other than for the up to [***] of expenses and fees of GTS per office action response or continuation that are recoverable in this Section 10.3 under the License Agreement, or to the extent that Ulthera specifically
requests the consultation and assistance of GTS: (i) a Party’s obligations to provide patent office communications, execute legal documents (e.g., Powers of Attorney, declarations, assignments), and provide status reports to the other
Party will be done at no expense to said other Party; and (ii) if a Party further chooses to have its own counsel review documents and provide input, said Party will be responsible for the expenses associated with same. 

(b) From time to time, to the extent that Ulthera desires to select other patents and patent applications for prosecution by Ulthera counsel,
Ulthera shall offer in writing to GTS to have such patents or patent applications be transferred to Ulthera’s counsel for prosecution, and to the extent GTS determines to accept such offer, not to be unreasonably withheld, then such patents or
patent applications shall fall under this Section 10.3. For the avoidance of doubt, all patents and all patent applications encompassed within GTS Patent Rights shall remain owned by, titled to and assigned to Licensors. 

(c) For those applications and patents identified as “Ulthera Prosecuted” on Exhibit A, Ulthera will provide a copy to GTS and its
counsel of all office actions and all responses to office actions, and to any draft continuations and other divisional or continuing patent applications in sufficient time prior to filing the same to allow GTS and its counsel to review the office
action and proposed filing and provide comments, and Ulthera will consider all comments and claims provided by GTS and will reasonably include such comments and claims in the filing. Ulthera shall endeavor to provide such office actions to GTS
counsel within one-month of receipt by a patent office, and shall provide a draft response at least two weeks prior to deadline for filing such response. Moreover, Ulthera will not knowingly make any statements or omissions or take any other action
during prosecution or enforcement of any Ulthera Prosecuted GTS Patent Rights which admits or concedes that any of such Patent Rights is invalid or unenforceable, or which adversely affects or limits the scope of any claims in such Patent Rights,
without GTS’ prior written consent. 
 (d) For those applications and patents identified as “Ulthera Prosecuted” on Exhibit A,
in the event of a dispute in amending claims, Ulthera shall make the final determination for claims that are solely within the Field and GTS shall make the final determination for all other claims. The parties agree that they will, in good faith,
attempt to resolve any disputes in favor of expediting prosecution. With 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
respect to a Party’s comments to an office action handled by the other Party’s counsel, such Party shall provide its comments in writing or telephonically within ten (10) business
days of receipt of any draft response from such other Party’s counsel; otherwise, such other Party’s counsel shall be free to proceed with its version of the draft response and only consider the comments provided by such Party in its own
discretion. 
 (e) Ownership of GTS Patent Rights. GTS will retain exclusive ownership of the GTS Patent Rights, as well as the exclusive
rights to exploit or otherwise use outside the Field. For those applications and patents identified as “Ulthera Prosecuted” on Exhibit A, Ulthera will notify GTS promptly of any patents or applications that it decides to irrevocably
abandon or not pursue the disclosed subject matter and will relinquish its prosecution rights and payment obligations back to GTS with respect to any such patents and applications [***], such relinquishment to include no more than [***] per calendar
year. For the avoidance of doubt, a patent application will not be considered irrevocably abandoned or not pursued if Ulthera chooses to file a continuing application in lieu of pursuing a parent application. For clarity, should Ulthera choose not
to prosecute and pay for a particular GTS patent or application, the patent or application shall still be licensed to Ulthera under the GTS Patent Rights, and no rights to Ulthera shall be forfeited. 

10.4 Payments for Prior Patent Prosecution as of Effective Date. Other than as specifically set forth in this Agreement, neither Party
shall have any right to a refund or reimbursement of any fees or costs accrued for any GTS Patent Rights as of the Execution Date of the Second Restated Agreement and thereafter. For the avoidance of doubt, Section 10.4 does not implicate the
obligations of the Parties relative to royalty payments under this and related Agreements. 
 10.5 Infringement by Third Parties. As
to the GTS Patent Rights: 
 (a) Ulthera shall have the exclusive right, but not the obligation, at its sole expense, under its control and
with counsel of its own choice, to enforce the GTS Patent Rights within the Field against any infringer, including the right to file suit for patent infringement naming GTS as a party, and the right to settle such suit without GTS’s consent.
Licensors shall promptly notify Ulthera in writing of any infringement by Third Parties of the GTS Patent Rights or of any Patent Rights covering GTS Know-How. 

(b) GTS shall permit the use of its name in all such suits, sign all necessary papers, and will attempt to do all reasonable things necessary
at Ulthera’s expense, to facilitate the prosecution of such infringement suits, so long as the business operations of GTS are not substantially disrupted. Ulthera shall incur no liability to GTS as a consequence of such litigation, the conduct
of such litigation or any unfavorable decision resulting from it, including any decision holding any of the GTS Patent Rights invalid or unenforceable. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c) Any recovery of damages by Ulthera by way of judgment, award, decree or settlement resulting
from any such suit pursuant to Section 10.4(a) shall be apportioned, after payment of all legal expenses and all other litigation costs, to the Parties based on their respective contributions to the legal expenses, litigation costs, and their
documented direct costs incurred in pursuing the suit. 
 ARTICLE 11 

Miscellaneous 
 11.1
Confidentiality. 
 (a) Ulthera and Licensors will be exchanging information relating to the Licensed Products at the inception of and
from time to time during the Term of this Agreement. Any such information which is considered by the disclosing Party to be confidential will be identified in writing as confidential information or, if disclosed orally or in another non-written
manner, shall be confirmed in writing as being confidential promptly within thirty (30) calendar days after the disclosure thereof (collectively referred to as “Confidential Information”). The Party receiving such information will
maintain the information in confidence using at least the same standard of care it uses to maintain its own information in confidence during the term of this Agreement and for a period of three (3) years thereafter. Such obligation of
confidentiality shall not apply to information which (i) is known to the receiving Party prior to the disclosure, (ii) is publicly known as of the date of the disclosure, (iii) becomes publicly known after the date of disclosure
through no fault of the receiving party, (iv) is received from a Third Party who has no obligation of confidentiality to the disclosing Party, (v) is developed independently by the receiving Party, or (vi) is required to be disclosed
under applicable laws, rules or regulations, including, without limitation, the rules and regulations of the Securities and Exchange Commission or other governmental bodies. 

(b) Notwithstanding paragraph (a) above, each Party shall be permitted to disclose to its suppliers, wholesalers and other direct
customers and assigns such Confidential Information relating to the Licensed Products as such Party shall reasonably determine to be necessary in order to effectively manufacture, market and distribute the Licensed Products provided that such
entities are bound by the same confidentiality obligation such Party has with respect to the other Party’s Confidential Information. Each Party shall also be permitted to disclose the Confidential Information if required to be disclosed to
comply with a court or administrative subpoena or order; provided, however, that the receiving party first uses reasonable efforts to obtain an order preserving the confidentiality of any Confidential Information, and provided, further, that the
receiving Party gives the other Party timely notice of the contemplated disclosure to provide the disclosing Party the opportunity to intervene to preserve the confidentiality of any Confidential Information. 

11.2 Publicity. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (a) No Party to this Agreement shall originate any publicity, news release or other public
announcement, written or oral, whether relating to this Agreement or any arrangement between the Parties other than acknowledging the existence of any arrangement between the Parties, without the prior written consent of any other Party named in
such publicity, news release or other public announcement, except where such publicity, news release or other public announcement is required by law; provided that in such event, the Party issuing same shall still be required to consult with the
other Party or Parties named in such publicity, news release or public announcement a reasonable time (being not less than forty-eight (48) hours) prior to its release to allow the named Party or Parties to comment on the use of its name and,
after its release, shall provide the named Party or Parties with a copy thereof. 
 (b) Neither Party shall use the name of the other for
advertising or promotional claims without the prior written consent of the other Party. 
 11.3 Survival. Those provisions of this
Agreement dealing with rights and obligations after termination of this Agreement shall survive termination of this Agreement to the extent necessary to give effect to such provisions. 

11.4 Penalties. If a Party terminates this Agreement in accordance with the terms herein, the terminating Party shall owe no penalty or
indemnity to the terminated Party on account of such termination. 
 11.5 Independent Contractor Status. Neither Party shall have any
authority to obligate the other in any respect nor hold itself out as having any such authority. All personnel of GTS shall be solely employees of GTS and shall not represent themselves as employees of Ulthera, all personnel of Ardent Sound shall be
solely employees of Ardent Sound and shall not represent themselves as employees of Ulthera, and all personnel of Ulthera shall be solely employees of Ulthera and shall not represent themselves as employees of GTS or Ardent Sound. 

11.6 Binding Effect; Benefits; Assignment. 

(a) This Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective permitted successors and assigns.
Nothing contained herein shall give to any other person any benefit or any legal or equitable right, remedy or claim. Anything to the contrary herein notwithstanding, each Party agrees that the right and obligations under this Agreement of the other
Party may, from time to time, be exercised or performed, as the case may be, in whole or in part by Affiliates of such Party; provided, however, that neither GTS nor Ardent Sound will engage or otherwise use any other Affiliate of either or any
Third Party to conduct the Development Services unless such Affiliates and Third Parties have entered into a prior written agreement with Licensors through which such Affiliates and Third Parties agree to protect any Confidential Information
provided by GTS or Ardent Sound under obligations no less stringent than those provided in Sections 11.1 and 11.2, and to assign to Licensors all Intellectual Property Rights arising from such engagement. In

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
any case under Title 11 United States Code, Licensors consent to the assumption by Ulthera of this Agreement upon satisfaction of statutory conditions of such assumption. 

(b) This Agreement shall not be assignable by any Party without the prior written consent of the other Party, which shall not be unreasonably
withheld, except that each Party shall be permitted to assign this entire Agreement without the other Party’s consent upon such Party’s Change of Control, or to an Affiliate or a Third Party acquiring all or substantially all of the
assigning Party’s assets, voting stock or business to which this Agreement relates, in each case upon written notice to the other Party; provided, however, that in event of such an assignment that Licensors shall continue to perform Development
Services until such Development Services are completed or terminated by Licensors in accordance with this Agreement. Any assignment of this Agreement by any Party, with or without any required consent of the other Party, shall be subject to the
assignee(s) agreeing in writing to assume all of the benefits and obligations of this Agreement. For clarity, any and all rights under this Agreement (other than the covenants-not-to-sue to New GTS Developments in the Field and to the Further GTS
Developments for the Treatment of [***], which convert to a non-exclusive license for a Third Party Acquirer upon acquisition, as set forth in Section 2.1(e)(ii)) are assignable, licensable, or otherwise transferable. 

11.7 Entire Agreement; Amendments. This Agreement, which includes the exhibits, sets forth the entire understanding among the Parties
and supersedes all prior agreements with respect to the subject matter herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective
authorized officers of the Parties, and no purchase order shall have the effect of modifying or amending this Agreement. 
 11.8
Severability. In the event that any provision of this Agreement would be held in any jurisdiction to be invalid, prohibited or unenforceable for any reason, such provision, as to such jurisdiction, shall be ineffective, without invalidating the
remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction. Notwithstanding the foregoing, if such provision could be more narrowly drawn while maintaining the intent of the
Parties, so as not to be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability
of such provision in any other jurisdiction. 
 11.9 Remedies. Unless otherwise expressly provided, all remedies hereunder are
cumulative, and in addition to any other remedies provided for by law and may, to the extent permitted by law, be exercised concurrently or separately, and the exercise of any one remedy shall not be deemed to be an election of such remedy or to
preclude the exercise of any other remedy. 
 11.10 Notices. Any notice, request, consent or communication (collectively, a
“Notice”) under this Agreement shall be effective if it is in writing and (a) personally 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
delivered, (b) sent by certified or registered mail, postage prepaid, return receipt requested, (c) sent by an internationally recognized overnight delivery service, with delivery
confirmed, or (d) sent by facsimile, with receipt confirmed and hard copy delivered by regular mail; in each instance, addressed as set forth in this Section 11.10, or to such other address as shall be furnished by either Party hereto to
the other Party hereto. A Notice shall be deemed to have been given as of (i) the date when personally delivered, (ii) seven (7) business days after being deposited with the United States Postal Service, certified or registered mail,
properly addressed, return receipt requested, postage prepaid, (iii) two (2) business days after being delivered to said overnight delivery service properly addressed, or (iv) confirmation of receipt of the facsimile, as the case may
be. All Notices shall specifically state: (1) the provision (or provisions) of this Agreement with respect to which such Notice is given, and (2) the relevant time period, if any, in which the party receiving the Notice must respond. 

If to GTS: 
 Guided Therapy Systems, LLC. 

33 S. Sycamore St. 
 Mesa, Arizona
85202 
 [***] 
 If to Ardent Sound: 

Ardent Sound, Inc. 
 33 S.
Sycamore St. 
 Mesa, Arizona 85202 

[***] 
 In either case, with a copy to (which
shall not constitute notice): 
 Quarles & Brady, LLP 

One Renaissance Square 
 Two North
Central Avenue 
 Phoenix, Arizona 85004 

[***] 
 If to Ulthera: 

Ulthera, Inc. 
 1840 South Stapley
Drive, Suite 200 
 Mesa, AZ 85204 

[***] 
 With a copy to (which shall not constitute
notice): 
 Knobbe, Martens, Olson & Bear, LLP 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2040 Main Street, 14th Floor 

Irvine, CA 92614 
 [***] 

11.11 Waivers. The failure of a Party to assert a right hereunder or to insist upon compliance with any term or condition of this
Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. The observance of any provision of this Agreement may be waived (either generally or in any
particular instance) only with the written consent of the waiving Party. 
 11.12 Counterparts. This Agreement may be executed in any
number of counterparts, and execution by each of the Parties of any one of such counterparts will constitute due execution of this Agreement. Each such counterpart hereof shall be deemed to be an original instrument and all such counterparts
together shall constitute but one agreement. 
 11.13 Headings & Terms. The article and section headings contained in this
Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Further, interchangeable use of the terms “Ulthera” and “Licensee” as well as the examples provided herein
for clarity or avoidance of doubt are not intended to be limiting. 
 11.14 Construction. The Parties expressly agree that any rule of
construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement. 

11.15 Further Assurances. Each Party will provide all further cooperation which any other Party reasonably determines is necessary to
effectuate the purposes of this Agreement, and to ensure such Party the full and quiet enjoyment of the rights provided hereunder, without limitation, executing further assignments, consents, releases and other commercially reasonable documentation,
and providing good faith testimony by affidavit, declaration, or other means. 
 [Signatures on following page] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, GTS, Ardent Sound and
Ulthera, intending legally to be bound hereby, have caused this THIRD AMENDED AND RESTATED LICENSE AND DEVELOPMENT
AGREEMENT to be duly executed as of the date first above written. 
  

			
	Guided Therapy Systems, L.L.C.
		
	By:	 	 /s/ M. Slayton

	Name:	 	Michael H. Slayton
	Title:	 	CEO/Manager
	Date:	 	
	
	Ardent Sound, Inc.
		
	By:	 	 /s/ Peter G. Barthe

	Name:	 	Peter Barthe
	Title:	 	President and CEO
	Date:	 	
	
	Ulthera, Inc.
		
	By:	 	 /s/ M. E. Likens

	Name:	 	Matthew E. Likens
	Title:	 	President and CEO
	Date:	 	

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 

GTS-EXCLUSIVELY LICENSED PATENT RIGHTS 

U.S. Patents 
  

																											
	 Country
	 	 	 Counsel

Reference
	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Two pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 Foreign Patents 
  

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 U.S. Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Three pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 Foreign Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Six pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 Expired/Abandoned Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Four pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 EXHIBIT B 

ARDENT SOUND-LICENSED PATENT RIGHTS 

U. S. Patents 
  

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Two pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 Foreign Patents 
  

																											
	 Country
	 	 	 Counsel

Reference
	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 U.S. Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Foreign Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Expired/Abandoned Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT C 

ARDENT SOUND NON-EXCLUSIVE PATENT RIGHTS 

Patents 
  

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Three pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT D 

ULTHERA PATENT RIGHTS 
 Patents

  

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Patent Applications 

 

																											
	Country	 	 	Counsel
Reference	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Two pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 Expired/Abandoned Applications 

 

																											
	 Country
	 	 	 Counsel

Reference
	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT E 

OTHER GTS DEVELOPMENTS 
  

																											
	TABLE E-1 – New GTS Developments	 
	 Country
	 	 	 Counsel

Reference
	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Four pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

																											
	TABLE E-2—Outside Field GTS Patent Rights	 
	 Country
	 	 	 Counsel

Reference
	 	 	Title	 	 	App No.
Filing Date	 	 	Pub No.
Pub Date	 	 	Patent No.
Issue Date	 	 	Comments	 
	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	[***]	Three pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions. 

 Exhibit F 

Ulthera [***] Treatment System 

[***] 

  

	[***]	Three pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested wtih respect to the omitted portions.EX-10.2

 Exhibit 10.2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 CONFIDENTIAL 
  

 
 MANUFACTURING SERVICES AGREEMENT 

between 
 JABIL CIRCUIT,
INC. 
 and 

Ulthera Inc. 

 INDEX 
  

							
	 SECTION 1 DEFINITIONS
	  	 	Page 1	  
		
	 SECTION 2 LIST OF SCHEDULES
	  	 	Page 4	  
		
	 SECTION 3 BUILD SCHEDULE FORECASTS
	  	 	Page 4	  
		
	 SECTION 4 MANUFACTURING SERVICES
	  	 	Page 4	  
			
	 4.1
	 	Testing	  	 	4	  
	 4.2
	 	Packaging and Shipping	  	 	4	  
	 4.3
	 	Items to be Supplied by Company	  	 	5	  
	 4.4
	 	Items to be Supplied by Jabil	  	 	5	  
	 4.5
	 	Company Inspection	  	 	5	  
	 4.6
	 	Materials Procurement	  	 	5	  
	 4.7
	 	Materials Declaration	  	 	5	  
	 4.8
	 	Product Evaluation	  	 	6	  
		
	 SECTION 5 WARRANTY & REMEDY
	  	 	Page 6	  
			
	 5.1
	 	Jabil Warranty	  	 	6	  
	 5.2
	 	Repair or Replacement of Defective Product	  	 	6	  
	 5.3
	 	Limitation of Warranty	  	 	6	  
	 5.4
	 	ECO Upgrade	  	 	7	  
		
	 SECTION 6 LIMITATION OF DAMAGES
	  	 	Page 7	  
		
	 SECTION 7 DELIVERY, RISK OF LOSS AND PAYMENT TERMS
	  	 	Page 7	  
			
	 7.1
	 	Payment	  	 	7	  
	 7.2
	 	Taxes	  	 	8	  
		
	 SECTION 8 IMPORT AND EXPORT
	  	 	Page 8	  
		
	 SECTION 9 DESIGN or REPAIR SERVICES: US GOVERNMENT CONTRACTS
	  	 	Page 8	  
		
	 SECTION 10 CHANGE ORDERS, RESCHEDULING AND CANCELLATION
	  	 	Page 8	  
			
	 10.1
	 	Changes to Manufacturing Services, Packaging and Shipping Specifications and Test Procedures	  	 	8	  
	 10.2
	 	Production Increases	  	 	9	  
	 10.3
	 	Product Configuration Changes and Engineering Changes	  	 	9	  
	 10.4
	 	Treatment of Obsolete/End-of-Life Material	  	 	9	  
	 10.5
	 	Rescheduled Delivery and Cancellation of Orders	  	 	9	  
	 10.6
	 	Termination Charges	  	 	10	  
	 10.7
	 	Duty to Mitigate Costs	  	 	11	  
		
	 SECTION 11 TERM 
	  	 	Page 11	  

  
 JBL073 

 

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

							
		
	 SECTION 12 TERMINATION
	  	 	Page 11	  
			
	 12.1
	 	Termination for Convenience	  	 	11	  
	 12.2
	 	Termination for Cause	  	 	11	  
	 12.3
	 	Termination for Bankruptcy/Insolvency	  	 	11	  
	 12.4
	 	Termination Consequences	  	 	11	  
		
	 SECTION 13 CONFIDENTIALITY
	  	 	Page 11	  
			
	 13.1
	 	Confidentiality Obligations	  	 	12	  
	 13.2
	 	Employees, Agents and Representatives	  	 	12	  
	 13.3
	 	Term and Enforcement	  	 	12	  
	 13.4
	 	Return of Proprietary Information and Technology	  	 	12	  
		
	 SECTION 14 INTELLECTUAL PROPERTY RIGHTS; ASSIGNMENT
	  	 	Page 13	  
			
	 14.1
	 	Jabil Existing Intellectual Property	  	 	12	  
	 14.2
	 	Jabil Created Intellectual Property	  	 	13	  
		
	 SECTION 15 MANUFACTURING RIGHTS
	  	 	Page 13	  
		
	 SECTION 16 COMPANY WARRANTY AND INDEMNIFICATION
	  	 	Page 13	  
		
	 SECTION 17 RELATIONSHIP OF PARTIES
	  	 	Page 14	  
		
	 SECTION 18 INSURANCE
	  	 	Page 14	  
		
	 SECTION 19 PUBLICITY
	  	 	Page 14	  
		
	 SECTION 20 FORCE MAJEURE
	  	 	Page 14	  

  
 JBL073 

 

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

							
		
	 SECTION 21 MISCELLANEOUS
	  	 	Page 14	  
			
	 21.1
	 	Notices	  	 	14	  
	 21.2
	 	Attorney’s Fees and Costs	  	 	15	  
	 21.3
	 	Amendment	  	 	15	  
	 21.4
	 	Partial Invalidity	  	 	15	  
	 21.5
	 	Monies	  	 	15	  
	 21.6
	 	Entire Agreement	  	 	15	  
	 21.7
	 	Binding Effect	  	 	16	  
	 21.8
	 	Waiver	  	 	16	  
	 21.9
	 	Captions	  	 	16	  
	 21.10
	 	Construction	  	 	16	  
	 21.11
	 	Section References	  	 	16	  
	 21.12
	 	Business Day	  	 	16	  
	 21.13
	 	Dispute Resolution	  	 	16	  
	 21.14
	 	Other Documents	  	 	16	  
	 21.15
	 	Counterparts	  	 	16	  
	 21.16
	 	Governing Law and Jurisdiction	  	 	17	  
		
	 SCHEDULES:
	  			
		
	 SCHEDULE 1—STATEMENT OF WORK
	  	 	19	  
		
	 SCHEDULE 2—CURRENCY POLICY
	  	 	21	  
		
	 SCHEDULE 3—MANUFACTURING SERVICES LETTER AGREEMENT (if applicable) 
	  			

  
 JBL073 

 

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 MANUFACTURING SERVICES AGREEMENT 

This Manufacturing Agreement (“Agreement”) is entered into by and between Jabil Circuit, Inc., a Delaware corporation (“Jabil”), having
offices at 10560 Dr. M.L. King Jr. Street North St. Petersburg, Florida 33716, on behalf of Jabil and its Subsidiaries, and Ulthera, Inc (“Company”), having its principal place of business at 2150 S. Country Club Drive, Suite 21,
Mesa, Arizona 85210. Jabil and Company are referred to herein as “Party” or “Parties”. 
 RECITALS 

A. Jabil is in the business of designing, developing, manufacturing, testing, configuring, assembling, packaging and shipping
electronic assemblies and systems. 
 B. Company is in the business of designing, developing, distributing, marketing and selling
products containing electronic assemblies and systems. 
 C. Whereas, the Parties desire that Jabil manufacture, test, configure,
assemble, package and/or ship certain electronic assemblies and systems pursuant to the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
 TERMS 

1 Definitions. In addition to terms defined elsewhere in this Agreement, the capitalized terms set forth below shall have the following meaning:

 1.1 “Additional Services” means services such as, design for manufacturability, manufacturing design test support,
computer assisted design for manufacturability, test development services, volume production and advanced packaging technologies all as specified and approved by Company and agreed to by Jabil. 

1.2 “Affiliate” means with respect to a Person, any other Person which directly or indirectly controls, or is controlled by,
or is under common control with, the specified Person or an officer, director or [***]% or more shareholder of the specified Person. For purposes of the preceding sentence, “control” of a Person shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the management or policies of such Person, or direct or indirect ownership (beneficially or of record) of, or direct or indirect power to vote, [***]% or more of the outstanding shares of
any class of capital stock of such Person (or in the case of a Person that is not a corporation, [***]% or more of any class of equity interest). 

1.3 “Build Schedule” means a manufacturing schedule provided to Jabil by Company in writing which specifies the Product to be
manufactured, including the quantity of each Product, its description and part number, shipping instructions and requested delivery date. 

1.4 “Build Schedule Forecast” means the monthly forecast provided to Jabil by Company, in writing, of quantity requirements of
each Product that Company anticipates requiring during the next twelve (12) month period. 
 1.5 “Commercially Reasonable
Efforts” means those efforts that would be deemed both commercially practicable and reasonably financially prudent after having taken into account all relevant commercial considerations. “Relevant commercial
considerations” shall be deemed to include, without limitation, (1) all pertinent 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 
facts and circumstances; (2) financial costs; (3) resource availability and impact; (4) probability of success; and (5) other commercial practicalities. 

1.6 “Components Supplied by Company” means those components or materials that Company provides, directly or indirectly, to
Jabil to be incorporated into the Product. 
 1.7 “EDI” shall mean electronic data interchange. 

1.8 “Effective Date” shall mean the date upon which the terms and conditions of this Agreement shall become effective by and
between the Parties. The Parties have agreed that the Effective Date of this Agreement shall be the 22nd day of December, 2011, or if no date is entered here, the last date of
signature. 
 1.9 “Fee and Price Schedule” shall mean the prices and fees set forth Schedule 1. 

1.10 “FOB” shall mean the shipper must at its own expense and risk transport the goods to the place of destination. 

1.11 “including” shall be defined to have the meaning “including, without limitation.” 

1.12 “in writing” shall mean written documents, EDI with phone confirmation, verified faxes and successfully transmitted
e-mails. 
 1.13 “Jabil Circuit, Inc.” and “Jabil” shall be defined to include any Jabil Subsidiary. 

1.14 “Jabil Created Intellectual Property” means any discoveries, inventions, technical information, procedures, manufacturing
or other processes, software, firmware, technology, know-how or other intellectual property rights newly created or developed, and reduced to practice by or for Jabil in manufacturing any Product provided pursuant to this Agreement, or
(ii) performing the Manufacturing Services or any other work provided pursuant to this Agreement; but shall not include any 
 (i) Jabil
Existing Intellectual Property, or (ii) Company Intellectual Property 
 1.15 “Jabil Existing Intellectual Property”
means any discoveries, inventions, technical information, procedures, manufacturing or other processes, software, firmware, technology, know-how or other intellectual property rights owned or developed by Jabil outside of this Agreement or owned
or controlled by Jabil prior to the execution of this Agreement that are used by Jabil in creating, or are embodied within, any Product, the Manufacturing Services or other work performed under this Agreement; and all improvements, modifications or
enhancements to the foregoing made by or on behalf of Jabil. 
 1.16 “Jabil Intellectual Property” shall mean both Jabil
Created Intellectual Property and Jabil Existing Intellectual Property, collectively. 
 1.16(a) Company Existing Intellectual
Property” means any discoveries, inventions, technical information, procedures, manufacturing or other processes, software, firmware, technology, know-how or other intellectual property rights owned or developed by Company, or owned or
controlled by Company, prior to or subsequent to the execution of this Agreement, that are provided by Company to Jabil under this Agreement embodied within, any Product, the Manufacturing Services or other work performed under this Agreement; and
all improvements, modifications or enhancements to the foregoing made by or on behalf of Jabil pursuant to this Agreement. 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 1.17 “Jabil Manufacturing Process” means Jabil’s process employed to
manufacture, test, configure and assemble Product manufactured for Company pursuant to the terms of this Agreement. 
 1.18
“Lead-time” means the mutually agreed upon minimum amount of time in advance of shipment that Jabil must receive a Build Schedule in order to deliver Product by the requested delivery date. 

1.19 “Loaned Equipment” means capital equipment (including tools) which is loaned to Jabil by or on behalf of Company to be
used by Jabil to perform the Manufacturing Services and includes all equipment, tools and fixtures purchased specifically for Company, by Jabil, to perform the Manufacturing Services and that are paid for in full by Company. 

1.20 “Manufacturing Services” means the services performed by Jabil hereunder which shall include but not be limited to
manufacturing, testing, configuring, assembling, packaging and/or shipping of the Product, including any Additional Services, all in accordance with the Specifications. 

1.21 “Materials Declaration Requirements” means any requirements, obligations, standards, duties or responsibilities pursuant
to any environmental, product composition and/or materials declaration laws, directives, or regulations, including international laws and treaties regarding such subject matter; and any regulations, interpretive guidance or enforcement policies
related to any of the foregoing, including for example: Directive 2002/95/EC of the European Parliament and of the Council of 27 January 2003 on the restriction of the use of certain hazardous substances in electrical and electronic equipment
(“RoHS”), Directive 2002/96/EC of the European Parliament and of the Council of 27 January 2003 on waste electrical and electronic equipment (“WEEE”), and European Union Member State implementations of the foregoing; the
People’s Republic of China (PRC) Measures for the Administration of the Control of Pollution by Electronic Information Products
(                      ) promulgated on February 28, 2006 (including any pre-market certification (“CCC mark”) requirements
thereunder and including relevant standards adopted by the PRC Ministry of Information Industry or other applicable PRC authority); PRC General Administration of Quality Supervision, Inspection and Quarantine’s Circular 441 (2006); Japanese
Industrial Standard C0950:2005; the California Electronic Waste Recycling Act of 2003; and/or other similar legislation. 
 1.22 “NRE
Costs” shall consist of expenses incurred by Jabil under this Agreement, including design engineering services, testing, fixturing and tooling and other out-of-pocket costs. 

1.23 “Packaging and Shipping Specifications” means the packaging and shipping specifications set forth in Schedule 1 and
otherwise supplied and/or approved by Company. 
 1.24 “Person” means any corporation, business entity, natural person,
firm, joint venture, limited or general partnership, limited liability entity, limited liability partnership, trust, unincorporated organization, association, government, or any department or agency of any government. 

1.25 “Product(s)” means the product(s) manufactured and assembled by Jabil on behalf of Company under this Agreement as
identified in Schedule 1 (or any subsequent Schedule 1 prepared for any product to be manufactured hereunder) including any updates, renewals, modifications or amendments thereto. 

1.26 “Proprietary Information and Technology” means software, firmware, hardware, technology and know-how and other
proprietary information or intellectual property embodied therein that is known, owned or licensed by and proprietary to either Party and not generally available to the public, including plans, analyses, trade secrets, patent rights, copyrights,
trademarks, inventions, fees and pricing information, operating procedures, procedure manuals, processes, methods, computer applications, programs and designs, and any processed or collected 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 
data. The failure to label any of the foregoing as “confidential” or “proprietary” shall not mean it is not Proprietary Information and Technology. 

1.27 “Specifications” means the technical specifications for manufacturing set forth in Schedule 1 and otherwise supplied
and/or approved by Company. Specifications may be amended from time to time by amendments in the form of written engineering change orders agreed to by the Parties. 

1.28 “SOW” means the statement of work for each Product set forth in any Schedule 1 as amended in writing from time to time
upon mutual agreement of the Parties. 
 1.29 “Subsidiary(ies)” means any corporation, partnership, joint venture, limited
liability entity, trust, association or other business entity of which a Party or one or more of its Subsidiaries, owns or controls more than 50% of the voting power for the election of directors, managers, partners, trustees or similar parties.

 1.30 “Suppliers Designated by Company” means suppliers designated, specified and/or approved by Company. 

1.31 “Test Procedures” means the testing specifications, standards, procedures and parameters set forth in Schedule 1 and
otherwise supplied and/or approved by Company. 
 1.32 “Unique Components” means those non-standard components or materials
procured exclusively for incorporation into the Product. 
 2 List of Schedules. This Agreement includes the following Schedules for each
Product to be manufactured hereunder, which are hereby incorporated herein and made a part of this Agreement: 
 Schedule
1—Statement of Work 
 Schedule 2—Currency Policy 

Schedule 3—Manufacturing Services Letter Agreement (if applicable) 

3 Build Schedule Forecasts. Within ten (10) business days following the execution of this Agreement, Company shall provide Jabil with a
Build Schedule Forecast. The Build Schedule Forecast shall be updated by Company, in writing, on at least a monthly basis. Any rescheduling or cancellation of the orders set forth in a Build Schedule Forecast shall be subject to the terms set forth
in Section 10.5. 
 4 Manufacturing Services. Jabil will manufacture the Product in accordance with the Specifications and any applicable
Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed
Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil
will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***]. 

4.1 Testing. Jabil will test the Product in accordance with the Test Procedures. Company shall be solely responsible for the
sufficiency and adequacy of the Test Procedures [***]. 
 4.2 Packaging and Shipping. Jabil will package and ship the Product
in accordance with Packaging and Shipping Specifications. Company shall be solely responsible for the sufficiency and adequacy of the Packaging and Shipping Specifications [***]. 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 4.3 Items to be Supplied by Company. Company shall supply to Jabil, according
to the terms and conditions specified herein, Company Proprietary Information and Technology and, if applicable, the Loaned Equipment, Components Supplied by Company and Unique Components necessary for Jabil to perform the Manufacturing Services.
Company will also provide to Jabil all Specifications, Test Procedures, Packaging and Shipping Specifications, Product design drawings, approved vendor listings, material component descriptions (including approved substitutions), manufacturing
process requirements, and any other specifications necessary for Jabil to perform the Manufacturing Services. Company shall be solely responsible for delay in delivery, defects and enforcement of warranties related to the Loaned Equipment,
Components Supplied by Company and Unique Components [***]. 
 4.4 Items to be Supplied by Jabil. Jabil will employ the Jabil
Manufacturing Process, any required manufacturing technology, manufacturing capacity, labor, transportation logistics, systems and facilities necessary for Jabil to perform the Manufacturing Services. Jabil will provide in writing to the Company a
high level description of the Jabil Manufacturing Process and any required manufacturing technology, manufacturing capacity, labor, transportation logistics, systems and facilities necessary for Jabil to perform the Manufacturing Services, for the
sole purpose of enabling Company to evaluate Jabil’s ability to perform under this Agreement. Any proprietary information provided to Company shall be considered as Jabil confidential under the terms of this Agreement. 

4.5 Company Inspection. Company shall have the right, upon reasonable advance notice, during normal business hours and at its
expense to inspect, review, monitor and oversee the Manufacturing Services, provided that such inspection shall not disrupt Jabil’s normal business operations. Company shall cause each of its employees, agents and representatives who have
access to Jabil’s facilities, to maintain, preserve and protect all Proprietary Information and Technology of Jabil and the confidential or proprietary information and technology of Jabil’s other customers. 

4.6 Materials Procurement. Jabil will use Commercially Reasonable Efforts to procure components, per Company’s approved
vendor list, necessary to fulfill mutually agreed upon Build Schedules. Company shall be responsible for the performance of suppliers and quality of the components.Jabil will provide procurement and engineering resources to support supplier failure
investigations where supplier does not meet delivery requirements and/or quality issues outside established specifications. Jabil will assist company in component failure analysis both internally and externally. Cost associated with the failure
analysis will be passed on to the Company upon mutual agreement 
 4.7 Materials Declaration. Company represents and
warrants that the Product is not subject to Materials Declaration Requirements. Where Company notifies Jabil in writing that the Product is subject to Materials Declaration Requirements, Jabil will use Commercially Reasonable Efforts to assist
Company in procuring parts, components and/or materials that are compliant with Materials Declaration Requirements. However, Company understands and agrees that: 

4.7.1 Company is responsible for notifying Jabil in writing of the specific Materials Declaration Requirements that Company determines
to be applicable to the Product and shall be solely liable for the adequacy and sufficiency of such determination and information; 

4.7.2 Any information regarding Materials Declaration Requirements compliance of parts, components, packaging or materials used in the
Products shall come from the relevant supplier. Jabil does not test, certify or otherwise warrant component, part, packaging or materials compliance, on a homogenous material level or any other level, with Materials Declaration Requirements; and

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 4.7.3 Company is ultimately and solely responsible for ensuring that any parts,
components or materials used in the Products, and the Product itself, are compliant with applicable Materials Declaration Requirements. 
 Notwithstanding
any other provision set forth in this Agreement, including amendments, attachments, or any other document incorporated herein, this Section 4.7 [***]. 

4.8 Product Evaluation. Company shall evaluate each Product to determine if it conforms, in all material respects, to the
Specifications. Company shall give Jabil written notice of any rejection of a Product within ten (10) business days following Company’s receipt of such Product (“Evaluation Period”). Such written notice of rejection of a Product
for failure to materially conform to the Specifications shall include a detailed and complete description of Company’s basis for asserting that the Product does not materially conform to the Specifications (“Specification Notice”). If
Company fails to provide such Specification Notice to Jabil within the Evaluation Period, such Product shall be deemed to comply with the Specifications. If Jabil disputes the basis for rejection set forth in a Specification Notice, it shall provide
written notice of the same to Company within ten (10) business days following receipt of the Specification Notice (“Notice of Disputed Defect”). Any such dispute shall be resolved by the Parties in accordance with the provisions of
Section 21.13. Any specified times for delivery of such Products set forth herein shall be tolled during the dispute resolution procedure set forth above. If Jabil does not dispute the basis for rejection set forth in a Specification Notice
Jabil shall follow its standard return process as set forth in Section 5.2 herein. The evaluation procedures set forth in this Section 4.7 shall apply to any redelivered Product. 

4.9 Materials kitting. Jabil will provide service to kit components to ship to Company for the purposes of transducer assembly
and testing. The kitting service will be subject to cost of materials [***]. 
 5 Warranty & Remedy. 

5.1 Jabil Warranty. Jabil warrants (i) that it will manufacture the Product in accordance with IPC-A 610 Class 2 workmanship
standard, and (ii) that at the time of manufacture, the Product will conform, in all material respects, to the Specifications. The above warranty shall remain in effect for a period of [***] from the date any Product is initially delivered to
Company or to Company’s designated carrier (“Warranty Period”). This warranty is extended to, and may only be enforced by, Company. 

5.2 Repair or Replacement of Defective Product. In accordance with Jabil’s standard return material authorization process
and procedure (“RMA”), Jabil will either repair or replace, in its sole discretion, any Product that contains a defect caused by a breach of the warranty set forth in this Section 5 provided that the Product is received within thirty
(30) days following the end of any applicable Warranty Period (“RMA Product”). If Company desires to return a Product based on a claim of breach of the warranty set forth in this Section 5, Company shall request an RMA number
from Jabil. Company shall then consign the alleged defective Product, FOB Jabil’s designated repair facility, and specify the Jabil assigned RMA number. Jabil will analyze any such RMA Product and, if a breach of warranty is found
(“Defect”), then Jabil will repair or replace the RMA Product within fifteen (15 ) business days of receipt by Jabil of the RMA Product and all required associated documentation. In the event a Defect is found, Jabil will reimburse Company
for the reasonable cost of transporting the RMA Product to Jabil’s designated repair facility and Jabil will deliver the repaired RMA Product or its replacement, FCA Company’s designated destination. [***] incurred to analyze and, if
requested by Company, repair or replace the non-Defective RMA Product and [***]. Limitation of Warranty. THE REMEDY SET FORTH IN SECTION 5.2 SHALL CONSTITUTE COMPANY’S SOLE AND EXCLUSIVE REMEDY FOR A BREACH OF THE WARRANTY MADE BY
JABIL HEREIN OR ANY OTHER OBLIGATION OF JABIL HEREUNDER. THE WARRANTY SET FORTH IN THIS SECTION 5 IS IN LIEU OF, AND JABIL EXPRESSLY DISCLAIMS, AND COMPANY EXPRESSLY WAIVES, ALL OTHER WARRANTIES AND REPRESENTATIONS OF ANY KIND WHATSOEVER WHETHER
EXPRESS, IMPLIED, STATUTORY, 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 
ARISING BY COURSE OF DEALING OR PERFORMANCE, CUSTOM, USAGE IN THE TRADE OR OTHERWISE, INCLUDING COMPLIANCE WITH MATERIALS DECLARATION REQUIREMENTS, ANY WARRANTY OF MERCHANTABILITY, OR FITNESS FOR
A PARTICULAR PURPOSE OR INFRINGEMENT OR MISAPPROPRIATION OF ANY RIGHT, TITLE OR INTEREST OF COMPANY OR ANY THIRD PARTY. COMPANY UNDERSTANDS AND AGREES THAT IT SHALL HAVE FULL AND EXCLUSIVE LIABILITY WITH RESPECT TO ANY PRODUCT, WHETHER FOR PRODUCT
DESIGN LIABILITY, PRODUCT LIABILITY, DAMAGE TO PERSON OR PROPERTY AND/OR INFRINGEMENT OR MISAPPROPRIATION OF THIRD PARTY RIGHTS. NO ORAL OR WRITTEN STATEMENT OR REPRESENTATION BY JABIL, ITS AGENTS OR EMPLOYEES SHALL CONSTITUTE OR CREATE A WARRANTY
OR EXPAND THE SCOPE OF ANY WARRANTY HEREUNDER. 
 JABIL’S WARRANTY SHALL NOT APPLY TO ANY PRODUCT JABIL DETERMINES TO HAVE BEEN SUBJECTED TO TESTING
FOR OTHER THAN SPECIFIED ELECTRICAL CHARACTERISTICS OR TO OPERATING AND/OR ENVIRONMENTAL CONDITIONS IN EXCESS OF THE MAXIMUM VALUES ESTABLISHED IN APPLICABLE SPECIFICATIONS, OR TO HAVE BEEN THE SUBJECT OF MISHANDLING, ACCIDENT, MISUSE, NEGLECT,
IMPROPER TESTING, IMPROPER OR UNAUTHORIZED REPAIR, ALTERATION, DAMAGE, ASSEMBLY, PROCESSING OR ANY OTHER INAPPROPRIATE OR UNAUTHORIZED ACTION OR INACTION THAT ALTERS PHYSICAL OR ELECTRICAL PROPERTIES. THIS WARRANTY SHALL NOT APPLY TO ANY DEFECT IN
THE PRODUCT ARISING FROM ANY DRAWING, DESIGN, SPECIFICATION, PROCESS, TESTING OR OTHER PROCEDURE, ADJUSTMENT OR MODIFICATION SUPPLIED AND/OR APPROVED BY COMPANY. 

5.4 ECO Upgrade. RMA’s for engineering change order (ECO) upgrades will also be subject to the RMA process. Jabil will
analyze the ECO and provide a per unit upgrade cost and expected completion and delivery date. 
 6 Limitation of Damages  

EXCEPT WITH REGARD TO ANY INDEMNITIES SET FORTH HEREIN, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY OTHER PERSON OR ENTITY
UNDER ANY CONTRACT, TORT, STRICT LIABILITY, NEGLIGENCE, OR OTHER LEGAL OR EQUITABLE CLAIM OR THEORY FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR INDIRECT DAMAGES, LOSS OF GOODWILL OR BUSINESS PROFITS, LOST REVENUE, WORK STOPPAGE, DATA LOSS,
COMPUTER FAILURE OR MALFUNCTION, OR FOR ANY AND ALL OTHER DAMAGES, LOSS, OR EXEMPLARY OR PUNITIVE DAMAGES WHETHER SUCH PARTY WAS INFORMED OR WAS AWARE OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE. THE FOREGOING SHALL NOT EXCLUDE OR LIMIT EITHER
PARTY’S LIABILITY FOR DEATH OR PERSONAL INJURY RESULTING FROM ITS NEGLIGENCE TO THE EXTENT THAT SUCH LIABILITY CANNOT BY LAW BE LIMITED OR EXCLUDED. 

7 Delivery, Risk of Loss and Payment Terms. For purposes of this Agreement delivery shall be FCA (per Incoterms 2000) Jabil’s facility and
deemed to have occurred, and all risk of loss shall be transferred to Company, when Product (or any other items) are tendered to the carrier approved by Company. The Fee and Price Schedule will be [***] on a [***] and will be [***] applicable to the
manufacture of the Product. [***] will not be included in the [***]. For any shipments where Jabil acts as an agent in completing the Shipper’s Export Declaration and managing Company’s exports on behalf of Company, where the Company is
the exporter of record (Principal Party in Interest—PPI), the Company hereby grants Jabil Power of Attorney to act on its behalf in managing its exports. 

7.1 Payment. Company shall pay Jabil all monies when due, including all NRE Costs associated with this Agreement. Payment of all
invoices shall be net forty-five (45) days from date of invoice. Payment to 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 
Jabil shall be in U.S. dollars and in immediately available funds. In the event any amounts are invoiced or paid in a different currency, the process in Schedule 2 “Currency Policy”
will apply. Company hereby unconditionally guarantees the payment by any of its subsidiaries or Affiliates who place orders under this Agreement to Jabil and/or its Affiliates. Any equipment, tooling, component, material or other goods or property,
which is purchased by Jabil in order to perform its obligations under this Agreement, shall become the property of Company once Jabil is reimbursed for all NRE Costs. Jabil shall invoice Company for actual outstanding NRE Costs and other monies due
at monthly intervals (or such other intervals as deemed appropriate) during the term of this Agreement and upon cancellation, termination or expiration of this Agreement. Jabil agrees to request advance written approval from Company should resource
requirements, and thereby NRE Costs, increase materially relative to estimated NRE Costs initially agreed by the Parties. Upon such request, Jabil shall provide to Company reasonably detailed supporting documentation and/or descriptions of the NRE
Costs for which Jabil seeks reimbursement. 
 7.2 Taxes. Company shall be responsible for all federal, foreign, state and local
sales, use, excise and other taxes (except taxes based on Jabil’s income), all delivery, shipping, and transportation charges and all foreign agent or brokerage fees, document fees, custom charges and duties. 

8 Import and Export. Company shall be responsible for obtaining any required import or export licenses necessary for Jabil to ship Product,
including certificates of origin, manufacturer’s affidavits, and U.S. Federal Communications Commission’s identifier, if applicable and any other licenses required under US or foreign law and Company shall be the importer of record.
Company agrees that it shall not export, re-export, resell or transfer, or otherwise require Jabil to ship or deliver any Product, assembly, component or any technical data or software which violate any export controls or limitations imposed by the
United States or any other governmental authority, or to any country for which an export license or other governmental approval is required at the time of export without first obtaining all necessary licenses and approvals and paying all duties and
fees. Company shall provide Jabil with all licenses, certifications, approvals and authorizations in order to permit Jabil to comply with all import and export laws, rules and regulations for the shipment and delivery of the Product. Company shall
also be responsible for complying with any legislation or regulations governing the importation of the Product into the country of destination and for payment of any duties thereon. 

9 Design or Repair Services; US Government Contracts. In the event that the Parties agree that Jabil will provide design or repair (i.e., out of
warranty) services for Company, or US government subcontract services for Company, the terms and conditions of such services shall be set forth in a mutually agreed upon separate agreement prior to the commencement of any such services. No FAR,
DFAR, or any other FAR Supplement clauses shall be applicable to this Agreement. If Company requires Jabil to perform any of the foregoing services prior to execution of a separate services agreement, Jabil’s services will be provided “as
is” and Company shall be fully responsible for any claims or liability arising from such services and corresponding deliverables or products. 
  

	10	Change Orders, Rescheduling and Cancellation. 

 10.1 Changes to
Manufacturing Services, Packaging and Shipping Specifications and Test Procedures. Company or Jabil may, in writing, request a change to the Manufacturing Services, Packaging and Shipping Specifications and Test Procedures at any time. Jabil
will analyze the requested change and provide Company with an assessment of the effect in writing that the requested change will have on cost, manufacturing, scheduling, delivery and implementation. Company will be responsible for all costs
associated with any accepted changes. Any such change shall be documented in a written change order and shall become effective only upon mutual written agreement of both Parties to the terms and conditions of such change order, including changes in
time required for performance, cost and applicable delivery schedules. 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 10.2 Production Increases. Company may, in writing, request increases in
production volume of Product for an outstanding Build Schedule at any time. Jabil will analyze the request and determine if it can meet the requested increase within the required Lead-time. If Jabil can satisfy the requested increase it will provide
Company with a new Build Schedule setting forth the expected delivery date of the changed order. If Jabil is unable to satisfy or comply with Company’s requested increase in production volume within the requested time frame for delivery, Jabil
will provide the reasons preventing Jabil from satisfying the requested increase within five (5) business days after receipt of Company’s request. Any such change shall be documented in a written change order and shall become effective
only upon mutual written agreement of both Parties to the terms and conditions of such change order, including changes in time required for performance, cost and applicable delivery schedules. 

10.3 Product Configuration Changes and Engineering Changes. Company may request configuration or engineering changes to Product
in writing at any time. Jabil will analyze the request and determine if it can meet the requested changes within the required Lead-time. If Jabil can satisfy the requested change it will provide Company within five (5) business days after
receipt of the configuration or engineering request notice, a notice of acceptance of the requested changes along with any additional costs and expected changes to delivery schedules. If Jabil is unable to satisfy or comply with Company’s
requested changes within the requested time frame for delivery, Jabil will provide the reasons preventing Jabil from satisfying the requested increase within five (5) business days after receipt of Company’s request. Any such change shall
be documented in writing and shall become effective only upon mutual written agreement of both Parties of the terms and conditions of such change, including changes in time required for performance, cost (including cost of materials on hand or on
order in accordance with original Build Schedule) and applicable delivery schedules. 
 10.4 Treatment of Obsolete/End-of-Life
Material. Upon receiving notice from Company of an engineering change or that any Product, component or assembly has become obsolete or has reached end-of-life for which Company is canceling any portion of a then-current Build Schedule,
Jabil will, within a reasonable period after receiving such notice, provide Company with an analysis of [***] for components and materials acquired or scheduled to be acquired to manufacture such Product under the relevant accepted Build
Schedule(s). Company’s [***]. Jabil will use Commercially Reasonable Efforts to assist Company in [***] by taking the following steps: 
  

	 	•	 	As soon as is commercially practical reduce or cancel component and material orders to the extent contractually permitted. 

  

	 	•	 	Return all components and materials to the extent contractually permitted. 

  

	 	•	 	Make all Commercially Reasonable Efforts to sell components and materials to third parties. 

  

	 	•	 	Assist Company to determine whether current work in progress should be completed, scrapped or shipped “as is”. 

10.5 Rescheduled Delivery and Cancellation of Orders. Company may request Jabil to reschedule the delivery date for Product(s)
and cancel pending orders in accordance with this Section 10.5. The charges to Company for deferring or accelerating delivery of an order (rescheduled) or cancellation of an order are outlined below: 

 

	a.	12 months forecast with following condition: see below 

  

	b.	[***] of Transducer. 

  

	c.	Transducer shelf life is 6 months after filled with liquid. If Ulthera wants to push out any one version during [***] Jabil will build the units but will [***]. The [***] will not be subjected to the charges set
forth in schedule 10.5 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

			
	Current plus 3 months	  	No changes to the total qty. Hard PO’s
		  	[***] for month 2 and onwards [***]
		  	Jabil will review the change request and notify Ulthera with-in 2 days if this request can be meet
	4th month to 6th month	  	[***]
	7th month to 9 month	  	[***]
	10th to 12th month	  	[***]

 In addition to the charges set forth above, Company shall be responsible for all inventory costs resulting
from a reschedule or cancellation. Such inventory costs shall be billed on a monthly basis [***], and shall be applied to the inventory applicable to the rescheduled or cancelled order. Reschedules in excess of the maximum deferred quantity or
period (set forth above) will be considered cancellations and subject to applicable cancellation charges. Reschedules and cancellations may result in [***]. In addition to the charges and costs set forth above, Company shall also be [***]. 

10.6 Termination Charges. Upon termination, expiration or cancellation of this Agreement for any reason, Jabil shall submit to Company
Jabil’s invoices for termination/cancellation charges within (a) sixty (60) days from the effective date of such termination, expiration or cancellation for materials and component costs and applicable margin and (b) sixty
(60) days after the end of the 6 month period following termination, expiration or cancellation for [***]. Jabil’s invoice for such charges shall be based upon costs incurred by Jabil up to the date of termination, expiration or
cancellation (“Termination Effective Date”) and shall also include the following: (i) costs accrued after the Termination Effective Date but resulting from such termination, expiration or cancellation; (ii) applicable margin in
all cases and (iii) [***] due to such termination, expiration or cancellation for up to six months from the date of the Termination Effective Date in accordance with U.S. Generally Accepted Accounting Principles. Jabil will provide to Company
all information reasonably necessary to confirm the [***] due to termination, expiration or cancellation. To the extent that Jabil cannot mitigate its costs as set forth in Section 10.7 below, upon cancellation, expiration or termination for
any reason, Company’s obligation shall be to pay the charges claimed by Jabil as follows: 
 10.6.1 The applicable price for the
Product of which Jabil has completed manufacture prior to the Termination Effective Date pursuant to an issued Build Schedule for which payment has not been made; 

10.6.2 Reimbursements for material acquisition costs, components, subassemblies and work-in-process at the time of Termination
Effective Date which were purchased or ordered pursuant to issued Build Schedules or Build Schedule Forecasts plus applicable margin; 

10.6.3 Jabil’s reasonable cancellation costs incurred for components, materials and subcontracted items that Jabil had on order on
behalf of Company on the Termination Effective Date pursuant to issued Build Schedules or Build Schedule Forecasts plus applicable margin; 

10.6.4 Except in the event of termination due to Jabil’s default hereunder, [***] up to six months after the Termination Effective
Date; and 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 10.6.5 Jabil’s [***] purchased by [***] specifically for the [***] under this
Agreement. All goods for which Company shall have [***] of [***] or more shall be held by Jabil for Company’s account and Company may arrange for its acquisition of them on AS-IS, WHERE-IS basis. 

10.7 Duty to Mitigate Costs. Both Parties shall, in good faith, undertake Commercially Reasonable Efforts to mitigate the costs
of termination, expiration or cancellation. Jabil shall make Commercially Reasonable Efforts to cancel all applicable component and material purchase orders and reduce component inventory through return for credit programs or allocate such
components and materials for alternate Company programs if applicable, or other customer orders provided the same can be used within thirty (30) days of the termination date. 

11 Term. The term of this Agreement shall begin on the Effective Date and shall end upon final payment to Jabil of all monies due to Jabil under
this Agreement. Notwithstanding the foregoing, Sections 4.1, 4.2, 4.3, 4.6, 5, 6, 7, 8, 10.4, 10.5, 10.6, 10.7, 11, 12.4, 13, 14, 15, 16, 17, 19 and 21 herein shall survive the expiration, cancellation or termination of this Agreement. 

12 Termination. This Agreement may be terminated as follows: 

12.1 Termination for Convenience. This Agreement may be terminated at any time upon the mutual written consent of the Parties or
upon the date for termination set forth in a written notice given by one Party to the other not less than one hundred and eighty (180) days prior to such date. 

12.2 Termination for Cause. Either Party may terminate this Agreement based on the material breach by the other Party of the
terms of this Agreement, provided that the Party alleged to be in material breach receives written notice setting forth the nature of the breach at least thirty (30) days prior to the intended termination date. During such time the Party in
material breach may cure the alleged breach and if such breach is cured within such thirty (30) day period, no termination will occur and this Agreement will continue in accordance with its terms. If such breach shall not have been cured,
termination shall occur upon the termination date set forth in such notice. 
 12.3 Termination for Bankruptcy/Insolvency. Upon
the happening of any of the following events with respect to a Party, this Agreement may be terminated immediately: 
 12.3.1 The
appointment of a receiver or custodian to take possession of any or all of the assets of a Party, or should a Party make an assignment for the benefit of creditors, or should there be an attachment, execution, or other judicial seizure of all or a
substantial portion of a Party’s assets, and such attachment, execution or seizure is not discharged within thirty (30) days. 

12.3.2 A Party becomes a debtor, either voluntarily or involuntarily, under Title 11 of the United States Code or any other similar law
and, in the case of an involuntary proceeding, such proceeding is not dismissed within thirty (30) days of the date of filing. 

12.3.3 The dissolution or termination of the existence of a Party whether voluntarily, by operation of law or otherwise. 

12.4 Termination Consequences. If this Agreement is terminated for any reason, Company shall not be excused from performing its
obligations under this Agreement with respect to payment for all monies due Jabil hereunder including fees, costs and expenses incurred by Jabil up to and including the Termination Effective Date. 

13 Confidentiality.  

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 13.1. Confidentiality Obligations. In order to protect both Parties’
Proprietary Information and Technology the Parties agree that each Party shall use the same degree of care, but no less than a reasonable degree of care, as such Party uses with respect to its own similar information to protect the Proprietary
Information and Technology of the other Party and to prevent any use of Proprietary Information and Technology other than for the purposes of this Agreement. This Section 13 imposes no obligation upon a Party with respect to Proprietary
Information and Technology which (a) was lawfully known to such Party before receipt from the disclosing Party; (b) is or becomes publicly available through no fault of the receiving Party; (c) is rightfully received by the receiving
Party from a third party without a duty of confidentiality; (d) is disclosed by the disclosing Party to a third party without imposing a duty of confidentiality on the third party; (e) is independently developed by the receiving Party
without a breach of this Agreement; or (f) is disclosed by the receiving Party with the disclosing Party’s prior written approval. If a Party is required by a government body or court of law to disclose Proprietary Information and
Technology, this Agreement or any portion hereof, then such Party agrees to give the other Party reasonable advance notice so that the other Party may seek a protective order or otherwise contest the disclosure. 

13.2. Employees, Agents and Representatives. Each Party represents and warrants to the other that it has adopted policies and
procedures with respect to the receipt and disclosure of confidential or proprietary information, such as the Proprietary Information and Technology with its employees, agents and representatives. Each Party represents and warrants to the other
Party that it will cause each of its employees, agents and representatives to maintain and protect the confidentiality of the other Party’s Proprietary Information and Technology. 

13.3. Term and Enforcement. The confidentiality obligation set forth in this Agreement shall be observed during the term of the
Agreement and for a period of five (5) years following the termination of this Agreement. Each Party acknowledges that a breach of any of the terms of this Section 13 may cause the non-breaching Party irreparable damage, for which the
award of damages would not be adequate compensation. Consequently, the non-breaching Party may institute an action to enjoin the breaching Party from any and all acts in violation of those provisions, which remedy shall be cumulative and not
exclusive, and shall be in addition to any other relief to which the non-breaching Party may be entitled at law or in equity. Such remedy shall not be subject to the arbitration provisions set forth in Section 21.13. 

13.4. Return of Proprietary Information and Technology. Upon the termination, cancellation or expiration of this Agreement all
Proprietary Information and Technology shall, upon written request, be returned to the respective Party, or at the respective Party’s discretion, destroyed by the receiving Party. 

14 Intellectual Property Rights; Assignment. 

14.1 Jabil Existing Intellectual Property. Jabil shall retain all right, title and ownership to any Jabil Existing Intellectual
Property. Jabil will not incorporate any Jabil Existing Intellectual Property into any Product without providing the Company with prior written notice describing with specificity the relevant Jabil Existing Intellectual Property. Upon full payment
of all monies due and owing under this Agreement, for the relevant Products, and all other monies due and owing to Jabil pursuant to any other related agreement executed by the Parties, for the relevant Products, Jabil will grant to Company a
worldwide, non-exclusive, fully paid-up, royalty free right and license under Jabil’s intellectual property rights to the Jabil Existing Intellectual Property only insofar as is required for Company to use, sell or distribute the Product
provided as part of the Manufacturing Services performed by Jabil pursuant to this Agreement; provided however, that no license to manufacturing processes and/or manufacturing process improvements shall be granted hereunder. 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 14.2 Jabil Created Intellectual Property. Jabil shall retain all right, title and
ownership to any Jabil Created Intellectual Property that is incorporated into any Product that is prepared as part of the Manufacturing Services or into any other work provided pursuant to this Agreement or any other related agreement executed by
the Parties. Upon full payment of all monies due and owing under this Agreement and all other monies due and owing to Jabil pursuant to any other related agreement executed by the Parties, Jabil will assign to Company all of Jabil’s right,
title and interest in and to the Jabil Created Intellectual Property. Company hereby grants to Jabil a worldwide, non-exclusive, irrevocable, fully paid-up, royalty-free right and license in and to the Jabil Created Intellectual Property. 

15 Manufacturing Rights. In consideration of the transfer by Jabil of the rights to the Jabil Intellectual Property, Company grants Jabil
exclusive manufacturing rights for one hundred percent (100%) of Company’s products that contain any Jabil Intellectual Property and/or any Company product containing a “derivative” of the Jabil Intellectual Property. For the
purposes of this Agreement, a derivative is defined as [***]. These manufacturing rights shall remain exclusive for the life of any Company product unless the Parties mutually agree that the term of manufacturing exclusivity shall be for a shorter
period as specifically set forth in any other related agreement executed by the Parties. In the event that manufacturing is subsequently transferred to a third party, Company and Jabil shall mutually agree upon the terms and conditions of, and shall
use Commercially Reasonable Efforts to facilitate, such transfer. In such event, Company shall, at a minimum, be liable for all monies due Jabil as set forth herein and any other monies due Jabil as set forth in any other related agreement executed
by the Parties. 
 16 Company Warranty and Indemnification.  

16.1 Except as set forth in Section 16.2 below, Company agrees to indemnify, defend and hold Jabil and its employees, Subsidiaries,
Affiliates, successors and assigns harmless from and against all claims, damages, losses, costs and expenses, including attorneys’ fees, arising from any recall, replacement or impoundment of any Product and any third party claims asserted
against Jabil and its employees, Subsidiaries, Affiliates, successors and assigns, that are based in part or in whole on any of the following: (a) Specifications, Company Proprietary Information and Technology, any Product, or any information,
technology and processes supplied and/or approved by Company or otherwise required by Company of Jabil; (b) actual or alleged noncompliance with Materials Declaration Requirements; (c) [***] infringes or violates any patent, copyright or
other intellectual property right of a third party, and (d) design or product liability alleging that any item in subsection (a) has caused or will in the future cause damages of any kind. Jabil may employ counsel, at its own expense to
assist Jabil with respect to any such claims, provided that if such counsel is necessary because of a conflict of interest with Company or its counsel or because Company does not assume control of the defense of a claim for which Company is
obligated to indemnify Jabil hereunder, Company shall bear such expense. Company shall not enter into any settlement that affects Jabil’s rights or interests without Jabil’s prior written approval, which shall not be unreasonably withheld.
Jabil will provide such assistance and cooperation as is reasonably requested by Company or its counsel in connection with such indemnified claims. 

16.2 Except as set forth in 16.1 above, Jabil agrees to indemnify, defend and hold Company and its employees, Subsidiaries, Affiliates,
successors and assigns harmless from and against all claims, damages, losses, costs and expenses, including attorneys’ fees, arising from any third party claims asserted against Company and its employees, Subsidiaries, Affiliates, successors
and assigns, that are based in part or in whole on any of the following: (a) an allegation that the manufacturing processes supplied by Jabil hereunder, infringe or violate any patent, copyright or other intellectual property right of a third
party, or (b) third party claims for bodily injury or tangible property damage to the extent such claim is based on a manufacturing defect solely and proximately caused by Jabil’s gross negligence or willful misconduct- Company may employ
counsel, at its own expense to assist Company with respect to any such claims, provided that if such counsel is necessary because of a conflict of interest with Jabil or its counsel or because Jabil does not assume control of the defense of a claim
for which Jabil is obligated to indemnify Company hereunder, Jabil shall bear such expense. Jabil shall not enter into any settlement that affects Company’s rights or interests without Company’s prior written approval, which shall not be
unreasonably withheld. Company will provide such assistance and cooperation as is reasonably requested by Jabil or its counsel in connection with such indemnified claims. 

17 Relationship of Parties. Jabil shall perform its obligations hereunder as an independent contractor. Nothing contained herein shall be
construed to imply a partnership or joint venture relationship between the Parties. The Parties 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 
shall not be entitled to create any obligations on behalf of the other Party, except as expressly contemplated by this Agreement. The Parties will not enter into any contracts with third parties
in the name of the other Party without the prior written consent of the other Party. 
 18 Insurance. Each Party will keep its business and
properties insured at all times against such risks for which insurance is usually maintained by reasonably prudent Persons engaged in a similar business (including insurance for hazards and insurance against liability on account of damage to Persons
or property and insurance under all applicable workers’ compensation laws). The insurance maintained shall be in such monies and with such limits and deductibles usually carried by Persons engaged in the same or a similar business. Jabil will
ensure that the Company is provided additional insured status via Jabil’s blanket additional insured coverage, as applicable, and, at Company’s request, will furnish to Company copies of certificates of insurance. 

19 Publicity. Without the consent of the other Party, neither Party shall refer to this Agreement in any publicity or advertising or disclose to
any third party any of the terms of this Agreement. Notwithstanding the foregoing, neither Party will be prevented from, at any time, furnishing any information to any governmental or regulatory authority, including the United States Securities and
Exchange Commission or any other foreign stock exchange regulatory authority, that it is by law, regulation, rule or other legal process obligated to disclose, so long as the other Party is given advance written notice of such disclosure pursuant to
Section 13.1. A Party may disclose the existence of this Agreement and its terms to its attorneys and accountants, suppliers, customers and others only to the extent necessary to perform its obligations and enforce its rights hereunder. 

20 Force Majeure. Neither Party will be liable for any delay in performing, or for failing to perform, its obligations under this Agreement
(other than the payment of money) resulting from any cause beyond its reasonable control including, acts of God; blackouts; power failures; inclement weather; fire; explosions; floods; hurricanes; typhoons; tornadoes; earthquakes; epidemics;
strikes; work stoppages; labor, component or material shortages; slow-downs; industrial disputes; sabotage; accidents; destruction of production facilities; riots or civil disturbances; acts of government or governmental agencies, including changes
in law or regulations that materially and adversely impact the Party, and U.S. Government priority orders or contracts; provided that the Party affected by such event promptly notifies (in no event more than ten (10) business days of discovery
of the event) the other Party of the event. If the delays caused by the force majeure conditions are not cured within sixty (60) days of the force majeure event, then either Party may immediately terminate this Agreement. Termination of this
Agreement pursuant to this Section 20 shall not affect Company’s obligation to pay Jabil, as set forth herein. 
 21
Miscellaneous. 
 21.1 Notices. All notices, demands and other communications made hereunder shall be in
writing and shall be given either by personal delivery, by nationally recognized overnight courier (with charges prepaid), by facsimile or EDI (with telephone confirmation) addressed to the respective Parties at the following addresses: 

 

							
	Notice to Jabil:	 		  	Jabil Circuit, Inc.	  	
		 		  	10560 Dr. M.L. King Jr. Street North	  	
		 		  	St. Petersburg, FL 33716	  	
		 		  	Facsimile:
(            )                            
                                  	  	
		 		  	Attn:                                     
                                         
             	  	
				
	with a copy to:	 		  	Jabil Circuit, Inc.	  	
		 		  	10560 Dr. M.L. King Jr. Street North	  	
		 		  	St. Petersburg, FL 33716	  	

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

							
		 		  	Facsimile: (727) 803-3415	  	
		 		  	Attn: General Counsel	  	
				
	Notice to Company:	 		  	Ulthera, Inc.	  	
		 		  	2150 S. Country Club Drive, Suite 27	  	
		 		  	  
	  	
		 		  	  
	  	
		 		  	Mesa, Arizona 85210	  	
		 		  	Attn: President	  	
				
	with a copy to:	 		  	The Phoenix Law Group	  	
		 		  	8765 E. Bell Road, Suite 110	  	
		 		  	    Scottsdale, AZ 85260	  	
		 		  	  
	  	
		 		  	  
	  	
		 		  	Attn: Joel J. Agena	  	

 21.2 Attorneys’ Fees and Costs. In the event that attorneys’ fees or other costs are
incurred to enforce payment or performance of any obligation, agreement or covenant between the Parties or to establish damages for the breach of any obligation, agreement or covenant under this Agreement, or to obtain any other appropriate relief
under this Agreement, whether by way of prosecution or defense, the prevailing Party shall be entitled to recover from the other Party its reasonable attorneys’ fees and costs, including any appellate fees and the costs, fees and expenses
incurred to enforce or collect such judgment or award and any other relief granted. 
 21.3 Amendment. No course of dealing
between the Parties hereto shall be effective to amend, modify, or change any provision of this Agreement. This Agreement may not be amended, modified, or changed in any respect except by an agreement in writing signed by the Party against whom such
change is to be enforced. The Parties may, subject to the provisions of this Section 21.3, from time to time, enter into supplemental written agreements for the purpose of adding any provisions to this Agreement or changing in any manner the
rights and obligations of the Parties under this Agreement or any Schedule hereto. Any such supplemental written agreement executed by the Parties shall be binding upon the Parties. 

21.4 Partial Invalidity. Whenever possible, each provision of this Agreement shall be interpreted in such a way as to be
effective and valid under applicable law. If a provision is prohibited by or invalid under applicable law, it shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the
remaining provisions of this Agreement. 
 21.5 Monies. All references to monies in this Agreement shall be deemed to mean
lawful monies of the United States of America. 
 21.6 Entire Agreement. This Agreement, the Schedules and any addenda attached
hereto or referenced herein, constitute the complete and exclusive statement of the agreement of the Parties with respect to the subject matter of this Agreement, and replace and supersede all prior agreements and negotiations by and between the
Parties. Each Party acknowledges and agrees that no agreements, representations, warranties or collateral promises or inducements have been made by any Party to this Agreement except as expressly set forth herein or in the Schedules and any addenda
attached hereto or referenced herein, and that it has not relied upon any other agreement or document, or any verbal statement or act in executing this Agreement. These acknowledgments and agreements are contractual and not mere recitals. In the
event of any inconsistency between the provisions of this Agreement and any Schedule and any addenda attached hereto or referenced herein, the provisions of this Agreement shall prevail unless expressly stipulated

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 
otherwise, in writing executed by the Parties. Pre-printed language on each Party’s forms, including purchase orders, shall not constitute part of this Agreement and shall be deemed
unenforceable. 
 21.7 Binding Effect. This Agreement shall be binding on the Parties and their successors and assigns;
provided, however, that neither Party shall assign, delegate or transfer, in whole or in part, this Agreement or any of its rights or obligations arising hereunder without the prior written consent of the other Party. Any purported assignment
without such consent shall be null and void. Notwithstanding the foregoing, Jabil shall have the right to assign its rights to receive monies hereunder without the prior written consent of Company. 

21.8 Waiver. Waiver by either Party of any breach of any provision of this Agreement shall not be considered as or constitute a
continuing waiver or a waiver of any other breach of the same or any other provision of this Agreement. 
 21.9 Captions. The
captions contained in this Agreement are inserted only as a matter of convenience or reference and in no way define, limit, extend or describe the scope of this Agreement or the intent of any of its provisions. 

21.10 Construction. Since both Parties have engaged in the drafting of this Agreement, no presumption of construction against any
Party shall apply. 
 21.11 Section References. All references to Sections or Schedules shall be deemed to be references to
Sections of this Agreement and Schedules attached to this Agreement, except to the extent that any such reference specifically refers to another document. All references to Sections shall be deemed to also refer to all subsections of such Sections,
if any. 
 21.12 Business Day. If any time period set forth in this Agreement expires upon a Saturday, Sunday or U.S. national,
legal or bank holiday, such period shall be extended to and through the next succeeding business day. 
 21.13 Dispute Resolution

 21.13.1 The Parties shall use good faith efforts to resolve disputes, within twenty (20) business days of notice of such
dispute. Such efforts shall include escalation of such dispute to the corporate officer level of each Party. 
 21.13.2 If the
Parties cannot resolve any such dispute within said twenty (20) business day period, the matter shall be submitted to arbitration for resolution. Arbitration will be initiated by filing a demand at the Phoenix , Arizona regional office of the
American Arbitration Association (“AAA”). 
 21.14 Disputes will be heard and determined by a panel of three arbitrators.
Each Party will appoint one arbitrator to serve on the panel. A neutral arbitrator will be appointed by the AAA. All arbitrators must have significant experience in resolving disputes involving electronic manufacturing and design services. 

21.15 Within fifteen (15) business days following the selection of the arbitrator, the Parties shall present their claims to the
arbitrator for determination. Within ten (10) business days of the presentation of the claims of the Parties to the arbitrator, the arbitrator shall issue a written opinion. To the extent the matters in dispute are provided for in whole or in
part in this Agreement, the arbitrator shall be bound to follow such provisions to the extent applicable. In the absence of fraud, gross misconduct or an error in law appearing on the face of the determination, order or award issued by the
arbitrator, the written decision of the arbitrator shall be final and binding upon the Parties. The prevailing 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 
Party in the arbitration proceeding shall be entitled to recover its reasonable attorneys’ fees, costs and expenses including travel-related expenses. 

21.16 Other Documents. The Parties shall take all such actions and execute all such documents that may be necessary to carry out
the purposes of this Agreement, whether or not specifically provided for in this Agreement. 
 21.17 Counterparts. This
Agreement may be executed by facsimile and delivered in one or more counterparts, each of which shall be deemed to be an original and all of which, taken together, shall be deemed to be one agreement. 

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 14.3 Governing Law and Jurisdiction. This Agreement and the interpretation of its
terms shall be governed by the laws of the State of Arizona , without application of conflicts of law principles. The provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. The
Parties hereby agree that the State and Federal Courts with jurisdiction over disputes arising in Pinellas County, Florida shall have exclusive jurisdiction over any litigation hereunder. 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 

 

							
	COMPANY	  	JABIL CIRCUIT, INC.
				
	By:	  	 /s/ William Fender
	  	By:	  	 /s/ Mohammed Mohiuddin

		  	Signature	  		  	Signature
				
	Name:	  	 William Fender
	  	Name:	  	 Mohammed Mohiuddin

		  	(Print)	  		  	(Print)
				
	Title:	  	VP, Operations	  	Title:	  	Business Unit Manager
				
	Date:	  	12/22/2011	  	Date:	  	12/22/2011

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 SCHEDULE 1 

TO MANUFACTURING SERVICES AGREEMENT 

BETWEEN JABIL AND COMPANY 

STATEMENT OF WORK 
 Product Description:
The Ulthera system consists of a re-usable, capital subsystems and a multi-patient use disposable subsystem. The re-usable subsystems include the Ulthera ® Control Unit and the Ulthera ® DeepSEE Handpiece. The multi-patient use disposable subsystem consists of the Ulthera ® DeepSEE ® 4 MHz, 4.5mm Transducer, Ulthera ® DeepSEE ® 7 MHZ, 3.0 Transducer, Ulthera ® DeepSEE ® 7 MHZ, 4.5 mm Transducer, Ulthera ® DeepSEE ® 7 MHZ,3.0mm Narrow Transducer, Ulthera ® DeepSEE ® [10 MHz, 1.5mm Transducer, and
the Ulthera ® DeepSEE ® 10 MHZ, 1.5mm Narrow Transducer. New products associated with Ulthera Systems will be added as needed 

 

	 	•	 	Specifications: Provided to Jabil as part of the requirements deliverable including BOM’s, drawings, models, specifications, work instructions 

 

	 	•	 	Quote with EAU and NRE cost: Exhibit A 

  

	 	•	 	Components and Materials Requirements: See note above for Specifications 

  

	 	•	 	Test Procedures: See note above for Specifications 

  

	 	•	 	Packaging and Shipping Specifications: See note above for Specifications 

  

	 	•	 	Suppliers Designated by Company: Customer BOM with AML (Approved Manufacturer List) 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 This page is intentionally left blank 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 SCHEDULE 2 

TO MANUFACTURING SERVICES AGREEMENT 

BETWEEN JABIL AND COMPANY 

CURRENCY POLICY 
 1) Jabil will invoice in
US dollars as agreed with Company in Section 7.1 of the Agreement, and remain fixed in that currency unless otherwise mutually agreed by both parties in writing. 

2) For materials that are purchased outside of the currencies identified in Section 7.1 of the Agreement, pricing will be [***]. 

3) Currency process: 
 [***] 

4) [***] 
 5) Calculation method: 

 

	 	a)	All references to “month” in this section shall be read as “calendar month.” 

  

	 	b)	The following details how certain currencies will be established: 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 Euro Based Currencies 

The Euro outright forward contract rates are calculated as follows [***]. 

United States Dollar Based Currencies 
 Rates against
United States Dollar are calculated as follows [***]. 
 Indian Rupee 

Rates for Indian Rupees are calculated as follows [***]. 

Brazilian Real 
 The Brazilian Real [***]. 

Mexican Peso 
 The spot rate for Mexican Peso, [***]. 

Malaysian Ringgit 
 Rates for Malaysian Ringgits are
calculated as follows [***]. 
 Chinese Renminbi 
 Rates
for the Chinese Renminbi [***]. 
 Other Currencies 
 For
other currencies not defined above, a mutually agreed process of establishing such rates will be defined. 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL 

 

 EHIBIT A 

Transducer Quote 
 [***] 

  

			
	 JBL073
	  	Manufacturing Services Agreement

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]